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Breast cancers are one of the most common Non dermatological cancers 
occurring in women and are one of the leading causes of cancer related deaths in 
women. It is reported that more than 1000000 cases occur world wide annually 
(Parkins DM et al 2001)
1 
 It is quintessential in clinical practice to understand the growth,  spread, 
and outcome of these tumours to give the patients a significant and comfortable  
long term survival. This needs a strict pattern of diagnostic, prognostic and 
treatment methods that shall take into account the behaviour of the tumour, 
characteristics of the treatment and milieu of the patient.  
The important prognostic information in breast cancers is provided by the 
clinical staging of the tumour and pathological grading. The various grading and 
staging methods use parameters like nuclear grade, tumour size, presence or 
absence of lymphatic and vascular invasion, axillary lymphnode involvement, 
sanctity of the resection margins and steroid receptor status.   
Nonetheless, 20-30% of these patients who had been accorded a favourable 
prognosis during or immediately after completion of treatment, do suffer relapses / 
recurrences within 5 years, while paradoxically some patients who were assigned a 
poorer prognosis initially, do survive for more than 10 years (Vincent Salomon A 
et al 2007)
2.
 Hence this throws up a very interesting question of what makes this 
difference. 
This paradox indicates the existence of certain factors that point to some 
specific biological nature of the tumour that subsumes all such existing and 
accepted parameters of prognostication this disease. The haematogenous 
dissemination of breast cancers is not significantly addressed in the present 
prognostic criteria, though they can occur independent of the spread by 
lymphogenous routes (Akiyama H et al 1994)
3
. Hence it is primarily imperative 
that all patients need to be searched for evidence for such haematogenous 
dissemination. The presence of bone marrow micro-metastases have been shown 
to be associated with such early treatment failures and hence to be considered as a 
poor prognostic factor in the treatment and management of patients with cancers of 
breast (Braun S et al 2005)
4.
 The presence of bone marrow disseminated tumour 
cells (DTC) is associated with a poor outcome for patients in stage I to III disease 
in Breast cancer. (Braun S et al loc. cit 2005). The dissemination is represented as 
either isolated or microaggregates of tumour cells, which have the potential to 
establish overt metastases at a later time, and are not detectable by serological tests 
such as tumour markers or by radiological imaging (Liotta LA et al 1991)
5
. These 
micro-metastases have been detected in approximately 90% of patients who have 
had curative therapy according existing protocols. This explains the frequent early 
tumour recurrences that occur in patients after such curative treatments (O’Brien et 
al 1995)
6
. Early spread of tumour cells usually remain undetected even by very 
high resolution imaging technologies. The CT scan detects peritoneal or hepatic 




Sensitivity and specificity of serum tumour antigen is limited. These 
techniques analyse the primary tumours for its DNA content, Oncogenes, Tumour 
suppressor genes and proliferative markers. They do not provide a direct measure 
of tumour burden of metastatic spread (Pandha HS et al 1995) 
8
.  
In contrast, the clearance of such metastatic cells from the bone marrow 
either spontaneously or as a response to targeted antibody therapy is seen to be 
associated with an improved patient survival . (Akiyama H et al loc.cit 1994). 
In this context, there is a real need for newer and more accurate methods for 
the identification of these disseminated tumour cells in the bone marrow. The 
current challenge for the pathologist is to improve and standardise the methods of 
early detection of DTC and hence this study is taken. 
AIMS AND OBJECTIVES 
 
1. To evaluate the Bone Marrow of patients with Breast Carcinoma for 
Disseminated Tumour Cells. 
2. To evaluate the relationship of the presence of Disseminated Tumour Cells 
in the Bone Marrow in patients with Breast Carcinoma with their Clinical 
stage, and Pathological parameters of the Primary Tumour.  
3. To compare and correlate the significance of the presence of Disseminated 
Tumour Cells in the Bone Marrow in relation to other prognostic factors. 
 
REVIEW OF LITERATURE 
The incidence of breast cancer has slowly increased over the past 20 years 
but now appears to have levelled off. Death rates have decreased during the last 25 
years because of earlier detection and better therapy. Currently, one in eight 
American women may be expected to develop breast cancer, one quarter of whom 
will die of the disease. In Western industrialized countries with high rates of breast 
cancer, the incidence of this tumour continues to increase throughout life.  
Epidemiology of Breast Cancers 
Breast Cancers are more common in women in socio economically 
developed countries like in North America, Western Europe and Scandinavia 
(Harris JR et al 1992)
9
. The disease is uncommon before the age of 35 years. 
(Holford TR et al1991)
10
.  Breast cancer is four to five times more frequent in 
Western industrialized countries than in developing countries. It has been 
suggested that diet, in particular dietary fat, may in part explain differences in the 
geographical distribution of breast cancer, but this concept remains controversial. 
Breast cancers accounts for nearly 32% of cancers in women (Jemal A et al                      
2003)
11 
Classification of Breast Cancers 
Breast Cancers are classified as Epithelial Tumours, Myoepithelial 
Tumours, Mesenchymal Tumours, Fibroepithelial Tumours, Tumours of the 
Nipple, Malignant Lymphomas and Metastatic Tumours (Tavossoli F A et al 
2001)
12
. Of these Epithelial Tumours / Carcinomas of the Breast are more common 
than the others. Epithelial Tumours of the Breast (Breast Carcinomas) are further 
classified into Ductal and Lobular Carcinoma (Susan C et al 2004)
13
. Of these, the 
Infiltrating Ductal Carcinoma of the Breast are more common constituting 90%. 
The most common histological subtype is NOS type of ductal carcinoma, that  
forms almost 70% of the cases (Dixon JM et al 1985)
14.
 The other variants of 
ductal carcinoma constitute 15-20%.  Lobular Carcinomas,   though unique 
accounts for 10-15% of the cases of breast carcinomas. The distribution of the 
different types of breast carcinomas (Table No 1) shows a similar worldwide 
variation. 
Table.1.Histologic types of invasive breast cancer in four large series before 
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Pathobiology of breast carcinoma 
The pathogenesis of breast cancer is poorly understood but epidemiologic, 
molecular and genetic studies outline complex risk factors. Breast cancers also 
exhibit diversity in histopathology, molecular features and overall patient 
outcomes. Hence, the disease can be viewed as a multifaceted and complex 
epithelial malignancy. The strongest association with an increased risk for breast 
cancer is a positive family history, specifically breast cancer in first-degree 
relatives (mother, sister & daughter). The risk is greater when the relative is 
afflicted at a young age or with bilateral breast cancer. Some of the major risk 
factors include the following.  
Table 2.  Risk Factors associated with breast cancer. 
 
Factor Relative Risk 
Well-Established Influences   
Geographic factors Varies in different areas 
Age Increases after age 30yrs 
Family history 
  First-degree relative with breast cancer 1.2-3.0 
  Premenopausal 3.1 
  Premenopausal and bilateral 8.5-9.0 
  Postmenopausal 1.5 
  Postmenopausal and bilateral 4.0-5.4 
Menstrual history  
  Age at menarche <12yrs 1.3 
  Age at menopause >55yrs 1.5-2.0 
Pregnancy 
  First live birth from age 25 to 29yrs 1.5 
  First live birth after age 30yrs 1.9 
  First live birth after age 35yrs 2.0-3.0 
  Nulliparous 3.0 
Benign breast disease 
  Proliferative disease without atypia 1.6 
  Proliferative disease with atypical hyperplasia >2.0 
  Lobular carcinoma in situ 6.9-12.0 
Less Well-Established Influences   
Exogenous estrogens   
Oral contraceptives   
Obesity   
High-fat diet   
Alcohol consumption   
Cigarette smoking   
Bilimoria MM,et al.(1995) 
19
. 
The factors also include: 1. Hormonal Status: A link between breast 
cancer and the hormonal status of women is strongly suggested by the association 
of (1) early menarche, (2) late menopause, and (3) older age at first pregnancy with 
an increased  risk of disease. Nulliparous women, or those who become pregnant 
for the first time after age 35 have a two to three fold higher risk of breast cancer 
than women whose first pregnancy occurred before age 18 (Wang DY et al 
1985)
20
. 2. Radiation: The female breast is susceptible to radiation induced 
neoplasia. The risk of breast cancer was increased in atomic bomb survivors and in 
women irradiated for postpartum mastitis Shore RE. et al.(1977)
21
 and Hodgkin 
disease; the highest risk occurred when exposure took place in childhood and 
adolescence (Hildreth NG et al 1983)
22
. Modern mammographic techniques use 
extremely low doses of radiation that are unlikely to pose a hazard (Goss PE et al 
1998)
23
 3. Previous Cancer of the Breast: Women who have previously had 
breast cancer have at least a 10-fold increased risk of developing a second primary 
breast cancer in the same or in the contra lateral breast. 4. Fibrocystic Change: 
Women with proliferative fibrocystic change and particularly those demonstrating 
atypical hyperplasia are at increased risk for cancer (Kern WH et al 1969)
24
 , 
(Steinhoff NG et al 1970)
25
. 
Genetic Factors in Breast Cancers: The major factors include: a. The 
BRCA1 gene (breast cancer 1), a tumour suppressor gene located on chromosome 
17q21 has been implicated in the pathogenesis of hereditary breast and ovarian 
cancers and possibly prostate and colon cancer. Mutations in this tumour-
suppressor gene are thought to be carried by 1 in 200 to 400 people in the United 
States. Germ line point mutations and deletions in BRCA1 confer a 60% to 85% 
lifetime risk for breast cancer, with more than half of the tumours developing 
before 50 years of age. It is currently suspected that mutated BRCA1 is responsible 
for 20% of all cases of inherited breast cancer and is responsible for about 3% of 
all breast cancers. Somatic mutations in BRCA1 are infrequently detected in 
sporadic breast cancers (Futreal PA et al 1994)
26
. b. The BRCA2 gene, located on 
chromosome 13q12, has been incriminated in approximately 20% of hereditary 
breast cancers. Women with one copy of a mutated BRCA2 gene have a 30% to 
40% lifetime chance of developing breast cancer. Like patients with BRCA1, these 
women have an increased risk of ovarian cancer. BRCA2 mutations also put male 
carriers at increased risk of breast cancer. Mutations of BRCA2 are particularly 
common among Ashkenazi Jewish women (Struewing JP 1997)
27
.    
c. The p53 gene is mutated in the Li-Fraumeni syndrome .Breast cancer will 
develop in almost all young women with the disease. Germ line (inherited) 
mutations in p53 account for 1% of breast cancers among women under the age of 
40 years. Somatic p53 mutations are common in sporadic breast cancers (Allered 
DC et al 1993)
28
. 
Clinical Presentation in Breast Cancers: Breast cancer often discovered 
by the woman or her physician is a deceptively discrete, solitary, painless, and 
movable mass typically 2 to 3 cm in size at diagnosis. Involvement of the regional 
axillary group lymph nodes is already present in about 45% patients. With 
mammography, these tumours are more frequently detected before they become 
palpable. The average invasive carcinoma found by screening is around 1 cm in 
size and only 15% of these have nodal metastases.  
Clinical Prognostication of Breast Cancers 
Prognosis is influenced by the following factors as emulated by the 
American Joint Committee on Cancer. American Joint Committee On Cancer: 
AJCC Cancer Staging Manual ,6
th
 edition. New York, Springer (2002)  
1. Size of Primary Tumour. Invasive carcinomas smaller than 1 cm have an 
excellent prognosis in the absence of lymph node metastases and may not 
require systemic therapy.  
2. Lymph node involvement. With no axillary node involvement, the 5-year 
survival rate is close to 90%. The survival rate decreases with each involved 
lymph node and is less than 50% with 16 or more involved nodes. Sentinel 
node biopsy introduced as an alternative is less morbid than a full axillary 
dissection; is identified by using a dye or a radioactive tracer and is highly 
predictive of the absence of metastatic carcinoma in the remaining lymph 
nodes. However, the clinical significance of the finding of micrometastases 
measuring less than 0.2 cm is still unclear.  
3. Distant metastases. Patients who develop hematogenous spread are rarely 
curable, although chemotherapy may prolong survival.  
4. Tumour Grading. The most common grading system for breast cancer 
evaluates tubule formation, nuclear grade, and mitotic rate to divide carcinomas 
into three groups.  
5. Histological Typing. All specialized types of breast carcinoma (tubular, 
medullary, cribriform, adenoid cystic, and mucinous) have a better prognosis 
than carcinomas of no special type ("ductal carcinomas").  
6. Receptor Studies. The presence of hormone receptors confers a slightly better 
prognosis and predicts response to therapy. The highest rate of response (80%) 
to anti-estrogen therapy like oophorectomy or tamoxifen is seen in women with 
both estrogen and progesterone receptors. Lowest rates of response (10%) is 
seen if both are absent.  
7. Proliferative Index. Proliferation is measured as  mitotic counts which are 
usually included in the grading systems or by flow cytometry or through 
immunohistochemical markers. High proliferative rates are associated with 
poor prognosis.  
8. Aneuploidy. Abnormal DNA content  have a worse prognosis.  
9. Overexpression of HER2/NEU. Overexpression of this membrane-bound 
protein, usually determined by immunohistochemistry or by fluorescence in 
situ hybridization is associated with a poorer prognosis.  
Based on the AJCC guidelines (Tavassoli FA and Devilee P,eds loc.cit 
2001), Breast carcinomas are divided into  clinical stages as follows:  
Stage 0. Ductal carcinoma in situ or Lobular carcinoma in situ (5-year 
survival rate: 92%). 
Stage I. Invasive carcinoma 2 cm or less in diameter (including carcinoma 
in situ with microinvasion) without nodal involvement (or only metastases < 0.02 
cm in diameter) (5-year survival rate: 87%). 
Stage II. Invasive carcinoma 5 cm or less in diameter with up to three 
involved axillary nodes or invasive carcinoma greater than 5 cm without nodal 
involvement (5-year survival rate: 75%). 
Stage III. Invasive carcinoma 5 cm or less in diameter with four or more 
involved axillary nodes; invasive carcinoma greater than 5 cm in diameter with 
nodal involvement; invasive carcinoma with 10 or more involved axillary nodes; 
invasive carcinoma with involvement of the ipsilateral internal mammary lymph 
nodes or invasive carcinoma with skin involvement (oedema, ulceration or satellite 
skin nodules), chest wall fixation, or clinical inflammatory carcinoma (5-year 
survival rate: 46%). 
Stage IV. Any breast cancer with distant metastases (5-year survival rate: 
13%)  
In quintessence, the prognosis of the patient depends on whether the tumour 
has spread or not.  
  
The most common cause of death in patients with breast carcinoma is 
metastatic disease (Panabieres CA et al  2007)
29
. Despite the numerous prognostic 
indicators currently in use, it is not fully possible to predict the outcome of 
treatment in most patients. This can be attributed in part to the metastatic 
behaviour of the tumour and the milieu intern of the patient. Though 
macrometastasis is not evident, the existence or absence of a minimal residual 
disease within the patient is not taken into account in the existing prognostic 
systems. The prediction of recurrences & relapses depend upon the presence of 
micro-metastatic foci in the patient at primary diagnosis (Catherine  CA et al.,loc. 
Cit 2007). 
Micrometastasis in Breast Cancer 
Stephan Braun et al., loc.cit (2005) in a pooled analysis has assessed the 
prognostic significance of the presence of bone marrow micrometastasis. The 
presence of micrometastasis was a significant prognostic factor with respect to 
poor overall survival and breast cancer specific survival. Hence a clear 
understanding of the tumour biology and tumour behaviour is essential to evaluate 
the patient responses and their outcome. 
Biology of Tumour Metastasis is the process by which discrete tumours form in a 
new site, often remote from the original parent neoplasm by seeding of tumour 
cells which arrive by active locomotion or passive transport through body fluids 
and subsequently grow progressively (Recamier JCA et al1829)
30
. Invasive breast 
cancer spreads primarily through the lymphatic and hematogenous spread. 
Sugarbaker EV set al (1982)
31
 have demonstrated that there is good statistical 
correlation between the size of the primary tumour and the incidence of metastasis 
for a number of common tumours including carcinomas of breast, colon, lung and 
malignant melanoma. However there are a significant number of patients in all of 
these tumour groups who either have small or clinically undetectable primaries 
with widespread large metastases or who have massive tumours and no 
secondaries because cell migration alone will not result in true metastasis. A 
number of steps are required for malignant cells to establish metastasis namely – 
(1) Invasion of the basement membrane underlying the tumour (2) Movement 
through the extracellular matrix (3) Penetration of vascular or lymphatic channels 
(4) Survival and arrest within the circulating blood or lymph (5) Exit from the 
circulation into a new tissue site (6) Survival and growth as a metastasis, a process 
that involves angiogenesis. The entire metastatic sequence from the initial binding 
of the tumour cells to the underlying extracellular matrix to the growth in a distant 
location depends on the expression of numerous molecules by the malignant cells 
like integrins, ICAM-1, MUC18,VCAM-1,E-cadherin, catenin(α,β), growth factors 
and cytokines.  
Autocrine motility factor (AMF), a tumour cell cytokine stimulates motility 
via a receptor mediated signalling pathway. Matrix metalloproteinases, a zinc- 
dependent endopeptidase which under normal circumstances is susceptible to 
tissue inhibitors of matrix metalloproteinases and the balance is strictly regulated. 
In contrast, metastatic phenotypes of cancer cells have a dysregulation of this 
balance leading to matrix metalloproteinases induced basement membrane and 
extracellular matrix degradation followed by invasion and spread to distant sites by 
vascular invasion or by local growth. Paget S et al (1889)
32
 reviewed the autopsy 
records of 735 patients dying of breast cancer at the Middlesex hospital and he 
drew the analogy that disseminating cancer cells are like seeds, which after being 
scattered on the wind grow only in sites (soil) that are congenial and this therefore 
came to be known as his seed and soil hypothesis of metastatic spread. LeeY.T.N 
et al (1983)
33
, Paget S et al loc.cit (1889) found that the incidence of deposits in 
bone in patients with breast cancer was approximately 70% compared with a figure 
of about 20% for other malignant tumours.  
Cancer dormancy is an apparent tumour free or latent state in which 
disseminated malignant cells are present but are under growth control by 
biological mechanisms. Withdrawal or inhibition of these restraining mechanisms 
lead to overt tumour progression. Dormancy may be induced in disseminated 
tumour cells by lack of primary tumour microenvironment such as absence of 
stimulating growth factors, presence of growth inhibiting cytokines control by 
inhibition of immune containment or by stimulation of protumourigenic 
mechanisms (Yuhas JM et al 1978)
34
, (Korah Ret al 2004)
35
. Transition from 
dormancy to progressive disease involves number of factors including genetic 
alterations in the cancer cells which enhance its survival and replication ability, 
immune escape capability and angiogenic potential of the tumour cells the relative 
ability to stimulate angiogenesis. According to Pierga JY et al (2005)
36
, UPAR 
(urokinase type plasminogen activator receptor) expression by bonemarrow 
disseminated tumour cells has been linked to a poor prognosis in a population of  









Bone Marrow Micro-Metastasis: Those metastatic stem cells with the 
capability to detach from the primary growth unlike most other cells within the 
primary tumour travel through the extracellular matrix and basement membrane 
into the circulation and exit by attaching and extravasating through the 
endothelium at another distant site i.e. Bone Marrow (Duffy MJ et al 1998)
37
. 
Bone marrow is a common homing organ for such tumour cells derived from 
various epithelial tumours including breast, prostate, lung and colon cancer (Zach 
O et al 2004)
38
. It is also reported that these tumour cells detected in the 
bonemarrow of patients need not preferably metastasize to the bone (Fidler U et al 
2003)
39
. Bone marrow might hence be an important reservoir of such tumour cells 
from where they may recirculate to other distant organs such as liver or lungs 
where better growth condition may exist. This view is consistent with Paget S et al 
loc.cit (1889) famous seed and soil concept. Tumour cells expressing CXC 
chemokine receptors on their cell membrane use these molecules to home to 








specific distant sites such as lung, liver and bonemarrow. CXCR4 is a G protein – 
coupled receptor, which plays a role in the chemo taxis of breast cancer cells. This 
cellular response is attributed to activation of the PI3K/PTEN/AKT/mTOR 
signalling pathway rather than the MAP/ERK pathway (Peng SB et al 2005)
40
. 
This pathway might be responsible for early spread of breast cancers as circulating 
cancer cells have been detected in the blood. Epithelial-mesenchymal transition 
and primary tumour micro vessel density may also be a factor in such spread of the 
tumour cells (Willipinski Stapelfeldt B et al 2005)
41
 . In addition, hypoxia is also 
discussed as a driving force that enables cells to leave the primary tumour. 
Hypoxia results in secondary processes    (E.g. proliferation, angiogenesis, and cell 
death) like release of hypoxia-inducible factor-1α which is significantly up 
regulated in bone marrow positive breast tumours (Woelfle U et al 2003)
42
 .  These 
cells are suitably labelled as Disseminated Tumour Cell (DTCs’).  
Disseminated Tumour Cells and Bone Marrow: Bone marrow is reported 
as a common homing site for DTC derived from breast cancer even in the absence 
of Lymph Node metastases or clinical signs of overt distant metastases (Pantel K 
& Brakenhoff RH 2004)
43
. It is also reported in various literature that disseminated 
tumour cells are present in bone marrow samples of 20-40% of patients even in the 
absence of lymph node metastases (stageN0).  The detection rate of DTC in Bone 
Marrow in breast cancer patients with no evident  metastasis has been reported to 
be in the range from 0% (Fetsch et al 2000)
44
 to 100% (Slade MJ et al. 2005)
45
. 
This illustrates the variability of results obtained by the use of different techniques 
or marker genes. In a recent large (more than 3500 cases) study of stages I–III 
breast cancer patients, the incidence of DTC in bone marrow detected by 
immunocytochemistry (ICC) ranged from 13 to 43% (Braun S loc.cit 2005). The 
presence of DTC in Bone Marrow may be useful not only in predicting the 
development of bone metastases, but also in predicting the development of 
metastases in other distant organs such as lung and liver. To date, however, it 
remains unknown whether bone marrow is a reservoir that allows for DTC to adapt 
and disseminate later into other organs or whether the presence of DTC in bone 
marrow might reﬂect the general propensity of these cells to disseminate and 
survive in organs, rather than just in the Bone Marrow. Until methods are 
developed to detect the presence of DTC in organs, such as the lung or liver, it will 
not be possible to distinguish between these two possibilities. That bone marrow 
could serve as a reservoir in breast cancer is supported by the presence of epithelial 
(cytokeratin positive) cells in the peripheral blood of patients with overt distant 
metastases years after the removal of the primary tumour. This suggests that 
tumour cells could break from bone marrow metastases to re circulate and 
disseminate to secondary tissues (Pantel K & Brakenhoff RH loc.cit 2004). This 
‘two-step’ metastasis model could explain why the DTC in patients with overt 
metastases closely resemble each other genetically (Klein CA et al 2002)
46
.  
According to Al-Hajj et al (2003)
47
 and Ginestier  C et al (2007)
48
 breast cancers 
are initiated and maintained by a small fraction of self renewing highly 
tumourigenic cells called ”Cancer Stem Cells”. In a study,   Balic M et al (2006)
49
 
concluded that bone marrow micro metastatic breast cancer cells exhibits a stem 
cell like Immunohistochemical phenotype. The hypothesis that stem cells may 
reside in the bone marrow is further strengthened by observations that most DTCs’ 
are non proliferating and resistant to Chemotherapy (Reya T et al 2001)
50
, (Zohu S 
et al 2001)
51
. According to Ring A et al (2004)
52
, in studies using antibody-based 
cytometric assays, cells with the characteristics of tumour cells have been shown 
in the peripheral blood of  0 to 100% of patients with operable (stages I–IIIa) 
breast cancer and 3–100% in patients with metastatic disease. The variability of 
results obtained in DTCs’ detection results from dramatic variations in 
methodology.  
Circulating Tumour Cells(CTC) in the blood stream is an important 
intermediate event in metastasis. While bone marrow aspirates are usually 
accessible, obtaining them can be both time consuming and invasive. Detection of 
CTC with the cells search system detects CTC using Ep-CAM coated beads for 
enrichment followed pan CK staining and provide significant prognostic 
information before and after initiation of chemotherapy in patients with metastatic 
breast cancer (Cristofanalli M et al 2004)
53
. Two immunocytochemical studies 
conducted by Muller V et al (2005)
54
,Pierga J V et al loc. cit (2005), showed that 
bone marrow was more frequently positive than blood CTC. 
Factors that may influence the variability in data in DTC detection include:  
1) Heterogeneity of the studied populations according to the: (a) Stage: The 
number of positive patients and the absolute numbers of DTC per patient rise 
as clinical stage rises (Ben Hsieh H et al 2006)
55.
 (b) Interval of time: 
separating surgery from the obtaining of DTC. Surgery may increase the 
number of breast cancer DTC (from 0 to 8000 cells/ml) in the peripheral blood, 
which persist for varying length of times in different patients (Hu XC et al 
2003)
56
. (c) Metastases location. The division of populations into those with 
early and metastatic breast cancer is probably simplistic. Moreover, metastasis 
sites could be missed when DTC are obtained leading to a misclassiﬁcation of 
the patient in the ‘early breast cancer’ category.  
2) Sample Handling and Preparation: (a) Delay between collection and 
analysis. (b) Conditions of sample storage (c) Contamination with normal 
epithelial cells. The introduction of skin cells into a sample at the time of 
puncture could lead to false positive results. Many investigators advocate that 
the ﬁrst few millilitres of sample are to be discarded to avoid such 
contamination. It has also been suggested recently that false positivity of single 
lymph node could result from iatrogenic displacement and transport of benign 
epithelial cells in patients with breast carcinoma (Bleiweiss IJ et al 2006)
57
.  
3) Criteria/Threshold of positivity: (a) Number of cells analysed. (b) Evaluation 
or not of the apoptotic status of analysed cells.  
4) Analytical and preanalytical (enrichment) techniques  
5) Markers. A number of different markers have been used. They may 
considerably vary the levels of sensitivity and speciﬁcity. 
Techniques in Detection of DTCs’: 
The methods to identify DTCs must distinguish between epithelial and 
other (mainly hematopoietic) cells. Secondarily, it may be desirable although not 
necessarily essential to distinguish between cancer and normal epithelial cells.  
The most conventional technique has been focussed on staining of 
previously embedded tissue in parafﬁn wax with two dyes, hematoxylin and eosin 
(H&E). It is likely that very small amounts of DTC present cannot be detected by 
this technique. An increase in sensitivity can be achieved by serial sectioning and 
histopathologic examination of an extensive number of sections. However, this 
approach is time consuming which hampers its routine application. More sensitive 
approaches have been developed. Immunohistochemistry (IHC), using antibodies 
that bind to more or less speciﬁc breast cancer cell marker(s) with ability to detect 
regions of metastases undetected by H&E staining is a well reported methodology 
(Cote RJ et al 1999)
58
. However, IHC has several drawbacks: it is a labour 
intensive and time consuming method particularly because at least 100000 cells 
need to be available for a reliable assessment of the presence of tumour cells  
(Silva J M et al  2001)
59
. Moreover, IHC requires a trained cytologist to conﬁrm 
the identity of the stained cells.  Although IHC has been previously applied to 
bone marrow smears, this technique is unable to make an accurate measurement of 
the frequently low DTC load within BoneMarrow (Gilbey et al 2004)
60
. Two 
major approaches involve antibody- and nucleic acid-based techniques to identify 
DTC in marrow smears.  
1. Antibody-based techniques: Approaches by ﬂuorescence microscopy, 
Immunocytochemistry and ﬂow cytometry analysis aim to isolate and 
enumerate individual tumour cells. Immunocytochemistry is still a gold 
standard for DTC detection, and most of the available clinical data have been 
gathered by immunocytochemistry screening, especially in Bone Marrow 
(Zieglschmid et al 2005)
61
.  
An advantage of this approach is that it may allow further characterization of 
the cells at a molecular level, in terms of expression of key biological markers, 
such as ERBB2 (ERBB2 gene ampliﬁcation estimated by FISH analysis) and 
morphological cell analysis. However, identiﬁcation of intracellular targets, 
such as cytokeratins, by antibodies needs cell permeabilization. As a 
consequence, cell viability is lost making the important discrimination of dead 
and viable DTC impossible. Since only viable cells might lead to metastasis, 
this valuable information cannot be assessed (Zieglschmid et al loc.cit 
2005).Like Immunocytochemistry, ﬂuorescence microscopy and Flow 
cytometry are labour intensive and time consuming, making these techniques 
too expensive for routine implementation. When compared with conventional 
techniques, qualitative ﬂuorescence microscopy and  Immunocytochemistry, 
Flow cytometry offers the advantage of a fully automated technique allowing 
quantitative measurements with high sensitivity, good resolution, speed, 
reproducibility and statistical reliability. For breast tumours, the most used 
targets for antibody-based techniques are the cytokeratins, ERBB2, MUC1 and 
TACSTD1. Many of the antibodies directed at epithelial and breast cancer cells 
are known to also stain haematopoietic cells also. Nonspeciﬁc staining of 
plasma cells can also occur due to alkaline phosphatase reaction against the 
kappa and lambda light chains on the cell surface (Smerage &Hayes et al 
2006)
62
. According to the antibody used, a false positive detection rate of 1–3% 
can be expected (Zieglschmid et al loc.cit 2005). Since tumour and epithelial 
speciﬁc cell marker antigens are expressed differentially in DTC, the use of a 
panel of monoclonal antibodies may help to enrich DTC and facilitate their 
detection, as notably shown by Hager et al. (2005)
63
. 
2. Nucleic acid-based techniques: Polymerase chain reaction(PCR), either 
qualitative or quantitative, has been used to identify and characterize DTC 
through the detection of genetic (allele-speciﬁc expression, microsatellite 
instability, loss of heterozygosity) and epigenetic alterations (methylation 
status) that are speciﬁcally associated with cancer cells (Sidransky D et al 
1997)
64
. This includes the search for tumour-associated point mutations in 
oncogenes or tumour suppressors. This latter PCR approach, however, is 
complicated by the substantial degree of genetic variability between tumours. 
For instance, TP53, the gene coding for p53 is mutated in about 25% of breast 
tumours, however, more than 1400 different mutations of this gene have been 
observed (Lacroix M et al 2006)
65.
Of note, PCR has been used to detect free 
DNA within plasma. For instance, the analysis of DNA methylation status of 
speciﬁc genes (ESR1, APC, HSD17B4, HIC1,RASSF1A) in serum of breast 
cancer patients has been shown to be of prognostic value (Muller V et al 
2003)
66.
 The PCR-based measurement of RASSF1A methylation has been used 
for monitoring efficacy of adjuvant tamoxifen therapy (Fiegl et al 2005)
67
. 
However, this use of PCR is limited by poor speciﬁcity. This is due in part to 
the high stability of DNA in plasma when compared with mRNA (Silva JM et 
al loc.cit  2002). As a result, it is unclear whether the free DNA that is 
ampliﬁed from plasma is from DTC present in plasma or if the DNA is being 
shed from primary tumours, metastatic tumours or from normal tissue (Ring A 
et al loc.cit 2004).   
  
Challenges with Detection of DTC  
This issue remains open for debate even today.  
1) Are These Definitely Cancer Cells? There are no criteria to unequivocally 
define cells as malignant, however the evidence strongly supports them as 
being malignant. Many detection methods depend on identification of epithelial 
specific markers.  However, not all cells that stain positive with epithelial anti-
cytokeratins can be unequivocally defined as malignant. Support for these cells 
as tumour cells is provided by molecular analyses and clinical studies showing 
their prognostic significance (Stathopoulou A et al 2002)
68
; (Xenidis N et al 
2006)
69
; (Ignatiadis M et al 2008)
70
.  
2) Are All Breast Cancer Cells Detected?  To be clinically useful, DTC 
detection must identify all breast cancer cell types. This is difficult, as there is 
great diversity in breast cancer biology coupled with great diversity in 
detection platforms. Variation in detection rates between techniques raises 
questions about whether different platforms are detecting different cells. 
Cytokeratins have become a widely used protein marker for the detection of 
epithelial tumour cells. With IHC, results depend on both the pattern of CK 
expression and the CK panel employed by the particular assay. Different 
antibodies may give different results for the same patient (Effenberger KE et al 
2010)
71
. A false negative result may result from loss of cytokeratin expression 
(e.g., loss of CK19 expression by cells that have undergone epithelial 
mesenchymal transition or treatment induced changes in CK expression in 
which  lack of  expression may be incorrectly interpreted as  the elimination of 
disease).  A recent preclinical study specifically assessed the ability of 
CellSearch to detect recognized breast cancer subtypes (Sieuwerts AM et al 
2009)
72
. In vitro genomic profiling confirmed the molecular subtype of 10 
breast cancer cell lines.  Two cell lines were selected from each of five 
following subtypes:  luminal A, luminal B, normal-like, basal, and HER2. 
From each cell line, 50–150 cells were injected into normal blood. CellSearch 
did not detect the normal-like subtype. These findings were not confirmed in a 
subsequent exploratory clinical study involving a limited number of patients (n 
= 58), in which CTC detection was reported in all subtypes, including normal-
like (CTC in 2 of 7 patients) (Bidard F et al 2009)
73
.Normal-like disease may 
be  aggressive with expression of cell markers, particularly with high CD44 
and high TWIST.1 expression and low CD24 expression. This is suggestive of 
their breast cancer stem cell like properties. Tests that recognize all breast 
cancer subtypes are required and further studies will address CTC detection 
across defined subtypes. 
3) Are DTC and CTC the Same Cells?  It is unclear if DTC and CTC are the 
same cells. If CTC measurements could replace DTC, this would be ideal, due 
to ease of collection of peripheral blood compared with invasive bone marrow 
sampling. Two studies, in which patients had both DTC and CTC assessment 
by IHC, showed a correlation between the two, but a higher rate of detection of 
DTC (Pierga JY et al 2004)
74
. This may be explained by the more constant 
presence of DTC in the bone marrow with sporadic shedding of CTC.  
4) Are These Cells Viable? A critical question is whether these cells are 
apoptotic cells or  they are viable cells capable of self-renewal and systemic 
metastases.  If they are viable, with self-renewal properties and  the capacity to 
deposit systemically and progress, they may provide important clinical 
information in the adjuvant setting.  If they are non-viable, their detection may 
have limited clinical meaning  in  early breast cancer. In contrast, in metastatic 
disease, the presence of CTC, viable or not, is shown to predict metastatic 
disease prognosis (Cristofanilli  M et al 2005)
75.
 
Applications of Disseminated Tumour Cell Detection in Breast Cancers  
1) Prognostication of Breast Cancers: Bonemarrow as the host organ of these 
DTCs’ is very accessible for tissue harvest and further analysis of Cohorts of 
breast cancer patients who had their initial surgery and in some patients 
adjuvant chemotherapy or hormonal therapy were followed with subsequent 
bone marrow sampling after surgery and prior to any further diagnosis of 
relapse. [1] In a study conducted by Mansi JL et al (1989)
76
 micro metastatic 
disease was identified in only 2-3% of cases where no evidence of relapse had 
previously been detected. In patients who subsequently developed either local 
or distant relapse, bone marrow metastasis had been identified in 19 and 30% 
respectively and in all 10 patients who developed bone metastasis disease.               
[2]. This lead to a conclusion that the increasing incidence of bone marrow 
metastasis in cases of women who subsequently developed recurrent local or 
distant disease is as a consequence of cells shedding from the original tumour 
and from aggressive dissemination of tumour cells in a metastatic fashion. 
According to studies conducted by Braun S (2000)
77
, Molino A et al (1999)
78
, 
Braun S et al loc cit (1999), pretreatment levels of bone marrow positivity were 
much higher with 49-51% of cases  showing bone marrow metastasis. This 
level do not change significantly after chemotherapy (44.1 %). The presence of 
DTCs’ after treatment was found to be an adverse independent prognostic 
factor. Persistence or disappearance of DTC after systemic treatment could 
therefore used as a surrogate marker of treatment response (Lacroix M et al 
loc.cit 2006). Studies have shown that adjuvant chemotherapy has no effect on 
the elimination of single dormant tumour cells in the bone marrow of high risk 
breast cancer patients (Quintela-Fandino M et al 2006)
79
.  
2) Adjuvant Therapy in Breast Cancers: Diel and coworkers (2006)
80
, 
randomized 302 patients known to have bone marrow metastasis to receive             
bisphosphonate clodronate ( 1600 mg daily  for 2 years). A statistically 
significant lower number of relapses were seen in the clodronate group . The 
number of deaths were also lower in the clodronate  group 6 versus 22 in 
control group (p= 0.001). This result was also consistent with a large study 
done by Powels.T et al (2006)
81
, involving 1069 patients with  operable stage            
1-3 breast cancer. This blinded  study randomized patients to receive 
clodronate or placebo and found that clodronate significantly improved the 5 
year relapse free survival by 31%. Zoledronic acid ,a more potent 
bisphosphonate than clodronate is under study. New agents –denosumab (AMG 
162) ,which is a fully human monoclonal antibody to Receptor activator of 
nuclear factor- kappa B ligand (RANKL- which is essential for the 
differentiation ,function and survival of osteoclast) is in clinical trial in women 
with breast cancer (Body JJ et al 2006)
82
. A therapeutic approach to bone 
marrow metastasis was utilised by Braun S and co-workers loc.cit(2005) who 
demonstrated that monoclonal antibody Edrecolomab or Traztuzumab directed 
against HER2 and EPCAM –positive cells in the bone marrow of breast cancer 
patients (Bozionelloli V et al 2004)
83
. 
Prognostic Importance of Disseminated Tumour Cells in Breast Cancers: 
In the usual clinical setting following a definitive surgery for early stage 
breast cancer, patients are free of overt disease. The aim of adjuvant therapy is 
eradication of residual microscopic malignancy based on the concept that residual 
disease is the source of subsequent incurable systemic relapse. However with 
current tools, the presence of minimal residual disease is presumed not measured.  
Our current approach for determining adjuvant systemic therapy is to assess the 
primary  tumour using traditional clinical and  pathological features  (e.g.,  patient  
age, tumour  grade, tumour size, lymph node involvement, hormone receptor (HR) 
expression, and expression of HER2)  or  more  recent  molecular profiling tools  
(e.g.,  21-gene Oncotype Dx  and  70-gene Mamma-print). Based on assessment of 
the primary tumour, risk of disease recurrence is estimated. The estimates are 
based on breast cancer relapse and overall survival data from prior clinical trials. 
Furthermore, following the presumption of the presence of residual disease, 
subsequent treatment decisions are based on characteristics of the primary tumour 
(e.g., HR, HER2) with the presumption that biological characteristics and 
treatment sensitivity are consistent between the primary tumour and 
micrometastases. There are no current tools in the adjuvant setting to assess 
treatment efficacy once a treatment has commenced (Oakman C et al 2010)
84
.  
Current adjuvant treatment is based on the following factors [1] Presence of 
residual disease [2] Consistent biological characteristics between residual disease 
and the primary tumour [3] Consistent treatment sensitivity between residual 
disease and the primary tumour. Using such an approach has its limitations. Some 
individuals with low risk disease develop recurrence despite treatment. Some 
individuals assessed as high risk remain relapse free in the long term without any 
systemic adjuvant therapy (Bonadonna G et al 2005)
85
.Such risk overestimation or 
underestimation by traditional methods is exemplified by the pivotal adjuvant 
chemotherapy trial in which 386 patients assessed as high risk, based on nodal 
involvement were randomized to either a surgery plus cyclophosphamide, 
methotrexate, and 5-fluorouracil trial (CMF) or to surgery alone.  Thirty year 
follow up data confirms a sustained survival benefit in the Chemotherapy & 
Surgery over Surgery alone with a relapse free survival (RFS): 29%  for the former 
vs. 22% for the later.  
It is hence important to note that 22% of patients had an excellent outcome 
despite apparent high-risk disease and no systemic treatment. Similarly, in a               
20 year  follow up of 90 patients, with estrogen receptor(ER) negative, node-
negative disease, randomized to surgery plus CMF versus  surgery alone, 
chemotherapy was associated with sustained benefit with RFS: 65% vs. 45% for 
the later (Bonadonna G et al loc.cit 2005). Again, substantial RFS was seen in a 
substantial number of patients treated with surgery alone. It may be thought that 
such risk overestimation may be overcome by recent molecular profiling tools. 
However, these tools are also shown to overestimate risk in a substantial number 
of women. The 21-gene Oncotype Dx was assessed in 355 placebo treated patients 
from the NSABP-B14 trial, all with node-negative, ER positive disease (Paik S et 
al 2005)
86
. Ten year distant-recurrence free survival (DRFS) for these patients 
treated with surgery alone was 86%, 62% and 69% for low, intermediate, and high 
recurrence scores respectively. For women with a high recurrence score, it would 
be reasonable based on current data to offer adjuvant systemic chemotherapy in 
addition to endocrine therapy. However, nearly 70% of women with a high 
recurrence score had long-term DRFS without any adjuvant intervention (Paik S et 
al loc.cit 2005).  
Similarly, one study from the Netherlands Cancer Institute Tissue Bank 
applied the 70-gene Mamma-print to 151 lymph node-negative patients, only 10 of 
whom received any adjuvant therapy. The research showed a 10-year distant 
metastases free survival of 87% for good signature patients and 44% for the poor 
prognosis cohort.  A striking feature of these current assessment tools in the 
adjuvant setting is overestimation of risk of disease recurrence. Some individuals, 
despite apparent ‘high risk’ disease, clearly have excellent long-term prognosis. 
Refined assessment, with identification of these individuals, would spare them 




In this setting, assessment of micrometastases is a promising alternative to 
presumption of residual disease. We now have tools to identify disseminated 
tumour cells (DTC) in the bone marrow.  Emerging evidence for the clinical 
potential of micro-metastases in breast cancer is reflected in their consideration 
within recent guidelines. Both the American Society of Clinical Oncology 2007 
Recommendations for the use of Tumour Markers in Breast Cancer and the San 
Gallen Consensus of 2009 reviewed evidence for micro-metastases (Harris L et al 
2007)
88
. While recognizing  available data, especially  for the strong prognostic 
role of  DTC and  acknowledging  the  future potential of these tools, the 
guidelines advise that  available evidence and  methodology  are insufficient to  
currently  support a routine role in the management of patients with breast cancer. 
Detection of micrometastases may have future value in early breast cancer for 
refining prognosis, monitoring treatment efficacy, and allowing bio-
characterization of residual disease. Potential roles for micrometastases in Breast 
carcinoma management include: [1] Refinement of prognosis [2] Serial detection 
to assess efficacy of adjuvant therapy and [3] Bio-characterization of residual 
disease, with potential therapeutic implications (Goldhirsch A et al 2009)
89
.  
Recent guidelines recommend that a positive DTC result is the presence of 
at least one CK positive cell in the bone marrow which meets morphological 
criteria for malignancy. These morphological features include large cells with a 
large nucleus, nuclear granulation or stippling, a large nucleolus, strong or 
irregular staining for cytokeratin, cytokeratin filaments, a high nuclear to 
cytoplasmic ratio, and the presence of cell clusters. (Fehm. T et al 2006)
90
. 
Morphological assessment distinguishes CK+ cells as DTC, haemopoietic, 
squamous, or normal epithelial cells. Whilst epithelial cells are rarely found in the 
bone marrow, they have been reported in 1–2% of normal volunteers. With 
morphology, DTC rates are approximately 13–15%. Other methods with the 
potential for increased accuracy of DTC detection include antibody-linked 
immunomagnetic enrichment, flowcytometry, PCR, and RT-PCR assays (Braun S 
et al loc.cit 2000). Detection of DTC at the time of surgery for the primary tumour 
in stage I-III breast cancer is an independent prognostic factor for poor outcome. 
Many studies show correlations between DTC and tumour size, tumour grade, and 
lymph node status. Several small studies have shown the poor prognostic 
significance of DTC in univariate analyses. The largest analysis of DTC in the 
bone marrow came from a pooled analysis of 4703 patients from 9 prospective 
studies with 10-year follow-up  (Braun S et al loc.cit 2005).  The pooled analysis 
was strengthened by the use of individual patient data.  
The presence of micrometastases was a significant and independent 
prognostic factor for poor overall survival, breast cancer specific survival, disease-
free survival, and distant disease-free survival. In multivariable analysis of death 
from breast cancer, DTC were an independent predictor of poor outcome. The 
median follow up among survivors was 62 months. For overall survival and breast 
cancer specific survival, the mortality ratios for micrometastases vs. no micro-
metastases were 2.44 (95% CI 2.08–2.86; p < 0.001) and 2.15 (95% CI 1.87–2.47, 
p < 0.001). Despite their clinical validity, there are concerns regarding analytical 
validity.  Assays are heterogeneous and are not clearly standardized or 
reproducible. The clinical utility of DTC is not clear. Due to the high correlation 
between DTC and high grade, large tumour size, and nodal involvement, many 
patients would already be considered candidates for systemic therapy without 
considering bone marrow status.  Conversely, for a patient with an apparently good 
prognosis with a small, node-negative, low grade tumour, it is unclear that a 
positive bone marrow result is sufficient to warrant differential recommendations 
for adjuvant therapy (Cote RJ et al loc.cit 1991). A comparative analysis of the 
various international studies on detection of DTC and the prognostication of Breast 
cancers is tabulated herewith. 
Table 3. Studies Evaluating the Prognostic Relevance of DTC in Bone 











Coombes et al 
(1986)
91 269 23 E29 Aspirate DFS 
Schlimok et al 
(1987)
92 155 18 CK18 Aspirate DDFS 
Porro et al (1988)
93 
159 16 Mbr1 Biopsy — 
Salvadori et al 
(1990)
94 121 17 Mbr1 Biopsy — 
Mathieu et al 
(1990)
95 93 1 KL1 Biopsy — 
Dearnaley et al 
(1991)
96 37 33 EMA Aspirate DFS, OS 
Cote et al  loc.cit 
(1991) 
49 37 T16, C26, AE-1 Aspirate DFS, OS 
Wiedswang et al 
(2003)




Harbeck et al 
(1994)
98 100 38 E29, 12H12 Aspirate DFS, OS
*
 
Diel et al (1998)
99 
727 43 TAG 12/2E11 Aspirate DFS, OS
*
 
Funke et al (1996)
100 
234 38 CK18 Aspirate ND 
Mansi et al (1999)
101 
350 25 E29 Aspirate DFS, OS 
Braun.S. et al loc.cit 
(2000) 
552 36 A45-B/B3 Aspirate DDFS, OS
*
 
Gerber et al 
(2001)
102 554 31 CK8, CK18, CK19 Aspirate DFS, OS
*
 
Gebauer et al 
(20010
103 393 42 CK/EMA Aspirate DFS,
*
 OS 
Braun.S. et al  
loc.cit (2005) 
(pooled analysis) 
4703 31 CK, mucin Aspirate DDFS, OS 
 
DFS indicates disease-free survival (significant correlation between 
positive bone marrow status and DFS); CK, cytokeratin; DDFS, distant DFS 
(significant correlation between positive bone marrow status and DDFS); EMA, 
epithelial membrane antigen; OS, overall survival (significant correlation between 
positive bone marrow status and OS); RT-PCR, reverse-transcriptase polymerase 
chain reaction; ND, not done. 
MATERIALS & METHODS 
  This study was proposed and conducted in the Tirunelveli Medical 
College Hospital.  A pilot study was done and approval of the ethical committee of 
the Tirunelveli Medical College & Hospital was obtained.  
 Patients who presented to the outpatient department of the Departments of 
Surgery and Oncology at Tirunelveli Medical College Hospital, during the period 
January 2009 to September 2010 with complaints of lumps in the breast were 
evaluated. Of the 385 patients examined 123 patients were found malignant on 
FNAC. Of these, 50 patients were selected for our study based on a set of inclusion 
and exclusion criteria.  
Inclusion Criteria 
1. Patients with FNAC positive for malignancy. 
2. Biopsy / Mastectomy proven Breast Carcinoma. 
3. Patients with no Radiological Bony Lesions.  
4. Patients with or without lymphatic spread. 
Exclusion Criteria 
1. Patients with carcinoma in situ. 
2. Patients with proven secondary metastasis. 
3. Patients with radiological bone lesions suspected as metastasis. 
4. Patients undergoing or have underwent chemotherapy / radiotherapy. 
5. History / existence of other cancers. 
  
FNAC was done with standard procedures and processd. Of these 123 
patients who were diagnosed as having a malignancy were evaluated in the 
respective departments using a standard proforma (Appendix 1). Of the 123 
patients with FNAC proven malignancies, 63 patients were subjected to surgical 
treatment  namely simple mastectomy / modified radical mastectomy / segmental 
mastectomy. The specimens were processed and reported at the Department of 
Pathology. These 63 patients were evaluated for macrometastatic disease and 
lymph node spread. Of these, 50 patients who had FNAC and Histopathology 
proven breast malignancies and no obvious radiological lesion were taken up for 
the study. 13 patients were not included in the study – 3 cases had Non Epithelial 
Tumours, 2 cases had secondary liver metastasis at diagnosis, 6 cases had already 
undergone adjuvant chemotherapy and or radiotherapy, 2 cases refused marrow 
evaluation.  
Written consent was obtained from the patient or her nearest relative after 
proper counselling. Bone Marrow aspirate was obtained from the 50 patients 
selected for the study. Bone Marrow aspirate was obtained by direct puncture of 
bilateral posterior  iliac crests under local anaesthesia with strict aseptic 
precautions. 2.5 ml of marrow was obtained. 10 Marrow Smears were prepared 
and fixed in methanol, of which 3 smears were stained with Leishman stain and 3 
with Haematoxylin and Eosin. 1 ml of the marrow was centrifuged using a 
Wintrobes tube and the gray column was aspirated and smears were prepared and 
stained similarly. The remaining material was allowed to clot in controlled 
temperature and fixed in 10% buffered formalin for 24 hrs and later processed 
using routine schedules and the serial sections stained with H&E were obtained 
and studied. (Appendix 2) 
The cases were evaluated for disseminated tumour cells using usual 
cytological parameters namely (1) cell size (2) cytoplasmic borders (3) nuclear 
size & nuclear cytoplasmic ratio (4) nuclear membrane irregularity (5) presence of 
nucleolus (6) hyperchromasia. Based on this evaluation, the patients were divided 
into two groups (1) DTC negative and (2) DTC positive. The Bone Marrow smears 
of the DTC positive patients were further evaluated using Pan Cytokeratin Stain 
(CK18). (Appendix 3)  
Cytomorphologic Features of DTC Detected by Immunocytochemical Staining 
using Cytokeratin Antibody: (Tanja Fehm, Stephan Braun et al loc.cit 2006.) 
1. Cell clusters 
2. Nuclear size clearly enlarged 
3. Strong and/or irregular cytoplasmic staining for cytokeratin 
4. Cytokeratin filaments may be seen 
5. Staining partially covers nucleus 
6. Large nucleoli may be seen 
7. High nuclear to cytoplasmic ratio 
8. Nucleus often granular or stippled 
The bonemarrow slides are interpreted as positive when Disseminated 
tumour cells are present in bone marrow and absence of cells with disseminated 
tumour cell morphology in corresponding negative controls and it is interpreted as 
negative when no disseminated tumour cells or presence of cells with disseminated 
tumour cell morphology in both anticytokeratin stained slides and in corresponding 
negative control slides 
The Mastectomy specimens obtained from these patients were studied 
according to existing pathology evaluation protocols and the prognostic parameters 
were tabulated. The tissue samples of the patients were also subjected to hormone 
receptor evaluation. 
The results and observations were tabulated, analysed and statistically 
evaluated for their significance. 
RESULTS AND OBSERVATION 
Three hundred and Eight five patients were referred to our FNAC OP for 
Breast Masses during the period January 2009 to September 2010. Of these, 123 
patients were diagnosed by FNAC as having a malignancy. Of these 63 patients 
were subjected to surgical treatment  namely simple mastectomy, modified radical 
mastectomy and or segmental mastectomy. (Table1) 
TABLE 1: GENERAL STATISTICS 
TOTAL NUMBER OF CASES REFERRED FOR 
BREAST FNAC 
385  
TOTAL NUMBER OF CASES OF BREAST FNAC 
FOUND MALIGNANT 
123 31.9% 
TOTAL NUMBER OF CASES WITH FNAC PROVEN 
BREAST MALIGNANCY WHICH WERE 
OPERATED  
63  
NO OF EPITHELIAL MALIGNANCIES 60 95.2% 
NO OF NON EPITHELIAL MALIGNANCIES 3  
 
Of the 60 patients with primary epithelial malignancies of the breast  10 
patients were not included in further study- 2 cases had secondary liver metastasis 
at diagnosis, 6 cases had already undergone adjuvant chemotherapy and or 
radiotherapy, 2 cases refused marrow evaluation. (Table 2) 
TABLE 2: THE STUDY GROUP 
NO OF PRIMARY EPITHELIAL MALIGNANCIES OF 
BREAST DIAGNOSED WITH HISTOPATHOLOGY 
60 
NO OF CASES SELECTED FOR STUDY  50 
NO OF CASES NOT SELECTED FOR STUDY 10 
 
Of the total 50 patients included in this study, all the 50 patients were 
studied using both marrow concentrate smears and marrow clot sections as 
referred to in the materials and methods of this study. Of the 50 patients studied 
with marrow concentrate sm
Tumour cells while only 1 patient (2%) was positive in clot sections.(Table 3)






  The diagnosis of DTC in the marrow preparation in 16 cases were reviewed 
with cytokeratin staining, of which 13 patients ( 81%) were positive.(Table 4) 
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Of the 50 patients included in this study 15 patients underwent simple 
mastectomy, while 34 patients underwent Modified radical mastectomy and 1 
patient had a segmental mastectomy done. Of the 15 patients who had Simple 
Mastectomy done 8 patients (53.3%) w
who had modified Radical Mastectomy 5 patients(
1 patient who had segmental mastectomy done
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 was negative for DTC. (Table 5)




15 8 7 
34 5 29 
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Of these 50 patients taken for the study, all 50 patients were subjected to 
bone marrow evaluation for Disseminated Tumour Cells. Of these 50 patients, 24 
patients were less than the median age of 52yrs and of which 3 patients were 
positive for DTC. 26 patients were above the median age ,of which 10 patients 
were positive for DTC. (Table 6)
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24 3 21 
 26 10 16 










Of the 50 patients studied 
were premenopausal (42%). Of the post menopausal group 11(37.9%) patients 
were DTC positive while only 2(9.5%) were positive in the premenopausal 
group.(Table 7) 
 





























29 patients were post menopausal (58%) while 21 
OUR CELLS
 TOTAL DTC + DTC 
 21 2 19
















The mastectomy specimen examined, and it was correlated that of the 50 
patients studied 12patients (24%) had a primary tumour size of less than 2cms 
(T1) of which 1 patient(8.3%) had DTC, 11 patients(22%)  had a primary tumour 
size of more than 2cms but le
DTC, 15 patients (30%) had a primary tumour size of more than 5cms 
which 4 patients (26.7%) had DTC and 12 patients (24%) had a primary tumour 
size of variable sizes with skin or chest wall infiltrates
(58.3%) had DTC.(Table 8)  
TABLE 8: TUMOUR SIZE & DISSEMINATED TUMOUR CELLS
TUMOR SIZE 
TI – LESS THAN 2cm
T2—2-
T3- >5cm
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TOTAL DTC + DTC 
 12 1 11
 5cm 11 1 10
 15 4 11
 
12 7 5 




















The mastectomy specimen examined, and correlated in the 50 patients 
studied shows that 18 patients (36%) had no lymphnode metastasis of wh
patient (5.6%) had DTC. 17patients (34
which, 6patients(35.3%) had DTC and 15 patients (30
metastasis of which, 6patients (40
lymphnode metastasis in our study group. (Table 9)
TABLE 9: LYMPHNODAL STATUS & DISSEMINATED TUMOUR CELLS
LYMPHNODE METASTASIS

























%) had N1 level lymphnode metastasis of 
%) had N2 level lymphnode 
%) had DTC. There were no N3 level 
 
 TOTAL DTC + DTC 
 
18 1 17
 17 6 11
 15 6 9
 0 0 0













Of the 50 patients studied all 50 patients (100%) had Infiltrating Ductal 
Carcinoma of Breast – Not Other wise Specified type. These cases were graded 
using the modified Bloom and Richardsons System of Grading 
1991)
104
.Of the 16 patients(
while of the 20 patients (40%)  with Grade II tumours, 5 patients (24%) had DTC, 
and of the 14 patients (28%) with Grade III tumours, 7 patients (66%) had 
DTC.(Table 10) 


























(Elston CW et al 
32%) with grade I tumor, 1 patient (10%) had DTC, , 
SEMINATED TUMOUR CELLS
 TOTAL DTC + DTC 
16 1 15
 20 5 15
 14 7 7 














Of the 50 mastectomy specimens 46 were subjected to hormonal receptor 
status evaluation. Of the 33 patients who were ER negative,
were positive for DTC. Of the 13 patients who were ER positive, no DTC was 
detected.(Table 11a) 
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Of the 50 mastectomy specimens 46 were subjected to hormonal receptor 
status evaluation. Of the 24 patients who were PR negative,12 patients (50%) were 
positive for DTC. Of the 22 patients who were PR 
positive for DTC.(Table 11b).





























 24 12 12
 22 1 21













All 50 Mastectomy specimens were screened for lymphovascular 
permeation and correlated with DTC status of the patients, Of the 17 patients(34%) 
who showed obvious lymphovascular permeation, DTC was positive in 12 patients 
(70.6%), while 1 patient (3%) was
lymphovascular permeation.(Table 12) 




The clinico-pathological characteristics and their correlation was studied 
and statistically analysed in terms of percentages and their differences were 
interpreted by Chi Square Test. The above statistical procedures were performed 



































TOTAL DTC + DTC 
 17 12 5 
 33 1 32 






 The incidence of breast cancer is gradually increasing over the past 20 years 
due to valuable and accurate diagnostic methodologies and increased awareness. 
But the morbidity and mortality have not fallen as expected, even in the presence 
of newer detection methods and better therapeutic options. Currently, one in eight 
American women may be expected to develop breast cancer, one quarter of whom 
will die of the disease. Many risk factors have been identified namely geographic 
factors which vary in different areas. The risk of breast cancer increases with age 
after the 3
rd
 decade, while a family history of breast cancer increases the risk by 
1.2-3.0 fold in the first degree relatives. There is also an 8.5-9.0 fold increase in 
risk in premenopausal women, while early menarche (<12yrs) and late menopause 
(>55yrs) also increases the risk considerably. The presence of benign breast 
diseases like proliferative diseases without atypia have a lesser risk of 1.6 times 
while Lobular carcinoma in situ have increased risks of 6.9-12.0 times. (Bilimoria 
MM Morrow M et al loc.cit 1995)  
The most common cause of death in patients with breast carcinoma is 
metastatic disease (Panabieres CA et al loc.cit 2007). Despite the numerous 
prognostic indicators currently in use, it is not possible to predict accurately the 
outcome of treatment in most of such patients. This can be attributed in part to the 
metastatic behaviour of the tumour and the milieu-intern of the patient. Though 
metastasis is not evident, the existence or absence of a minimal residual disease 
within the patient is not taken into account in the existing prognostic systems. The 
prediction of recurrences & relapses depend upon the presence of micro-metastatic 
foci in the patient at the time of primary diagnosis. (Panabieres CA et al loc.cit 
2007). Thus the existence of micro-metastatic foci in the bone marrow was studied 
widely  and various authors have come up with variable analyses and conclusions.  
Weidswang.G et al 2003 (Table A) in their prospective analysis of the 
clinical relevance of detection of isolated tumor cells in breast cancer patients have 
studied a total of 817 patients. Of these 817 patients, 108 (13.21%) were positive 
for DTC. Of the 817 patients, 231 (28.3%) were in the premenopausal age and 503 
(61.6%) were in the postmenopausal age while in 83 (10.1%) menopausal status 
was not known. Of the pre-menopausal patients 31 (13.4%) were positive for 
DTC, while 68 (13.5%) patients who were postmenopausal were positive for DTC. 
The P value was 0.964 hence reported insignificant. In this study, 513 of the 
patients (62.8%) had no lymphnode metastasis of whom 50 (9.7%) had DTC. 172 
patients (21%) had N1 level lymphnode metastasis of whom 26 patients(15%) had 
DTC and 105 patients (12.8%) had N2&N3 level lymphnode metastasis of whom 
30 (28.5%) had DTC. In 28 patients (3.4%) the lymphnode status was not known 
of whom 2 patients (7.1%) had DTC. The P value was 0.001 which was reported 
significant and hence had a positive correlation in this study. In this study, 496 
patients had T1 tumour status of whom 55 (11.1%) had DTC, 252 patients (30.8%) 
had T2 tumour status of whom 37 (14.7%) had DTC and 47 had a combined 
tumour status of T3&T4 of whom 11 (23.4%) were positive for DTC. Of the 22 
patients (2.7%) in whom tumour status was not known, 5 were positive for DTC. 
The P value was 0.011 and hence reported to have a positive correlation in this 
study. While correlating the histological grading, 617 patients had grade I of which 
78 (12.6%) were positive for DTC, 156 patients had grade II of which 26 (16.7%) 
were positive for DTC, 203 patients had grade III of which 29 (14.3%) were 
positive for DTC while in 16 patients the histological grade was not known, of 
whom 2 (12.5%) were positive for DTC. The P value was 0.164 and hence was 
reported as not significant. Of the 143 patients (17.5%) who had lymphovascular 
permeation, DTC was positive in 25 (17.5%), while 29 (17.5%) were positive for 
DTC without lymphovascular permeation. Of the 198 patients who were ER 
negative, 33 patients (16.7%) were positive for DTC, while in contrast of the 582 
patients who were ER positive, 69 patients (11.9%) were positive for DTC. The P 
value was 0.083 which is not significant. The relation between DTC & 
Progesterone receptor status was reported as not significant. But it is still important 
to note that DTC was positive in patients with ER & PR negativity. 
In this study the authors have highlighted the following intricacies stressing 
the importance of DTC in Breast Cancer prognosis. The combination of tumor, 
hormone receptor status, and Bone Marrow status can categorize node-positive 
patients into a low risk group and a high-risk group for predicting early disease 
progression. By combining these, approximately 30% of the node-positive patients 
could be placed into low risk group. Meanwhile tumor size greater than 2 cm, 
receptor negativity, and/or BM-positive  status predict a high systemic relapse rate. 
This study also confirms that the occurrence of DTC in Bone Marrow predicts the 
future systemic relapses and death from breast cancer, and hence the detection of 
these cells is to be considered as an independent prognostic factor for systemic 
relapses and breast cancer specific deaths. The proportion of positive Bone  
Table A: CLINICOPATHOLOGICAL CORRELATION OF THE PATIENT AS IN 




TOTAL BM-DTC p-VALUE 




PRE 231 28.3 31 13.4 
0.964 POST 503 61.6 68 13.5 




N0 513 62.8 50 9.7 
<0.001 
N1 172 21 26 15 
N2&N3 105 12.8 30 28.5 
NX 28 3.4 2 7.1 
TUMOUR STATUS 
 
T1 496 60.7 55 11.1 
0.011 
T2 252 30.8 37 14.7 
T3&T4 47 5.8 11 23.4 
TX 22 2.7 5 22.7 
HISTOLOGY 
 
DUCTAL 617 75.5 78 12.6 
0.188 LOBULAR 156 19.1 26 16.7 




I 199 24.4 19 9.5 
0.164 
 
II 399 48.8 58 14.5 
III 203 24.8 29 14.3 
UNKNOWN 16 2 2 12.5 
ER STATUS 
 
POSITIVE 582 71.2 69 11.9 
0.083 NEGATIVE 198 24.2 33 16.7 
UNKNOWN 37 4.5 6 16.2 
PR STATUS 
POSITIVE 461 56.4 46 10 
0.191 NEGATIVE 313 38.3 53 16.9 
UNKNOWN 43 5.3 9 21 
HORMONAL STATUS 
POSITIVE 622 76.1 73 11.7 
0.051 NEGATIVE  166 20.3 29 17.5 
UNKNOWN 29 3.5 6 21 
VASCULAR 
INVASION 
POSITIVE 143 17.5 25 17.5 
0.103 NEGATIVE 569 69.5 70 12.3 
UNKNOWN 105 12.9 13 12.4 
TYPE OF SURGERY 
CONSERVATIVE 252 30.8 22 8.7 
0.042 
MASTECTOMY 546 66.8 83 15.2 
 
Weidswang.G, Borgen.E, Karesen.R etal Detection of Isolated Tumour 
Cells in Bone Marrow is an independent prognostic factor in Breast Cancer; 
JClin Oncol 2003; 21: 3469-3478 
Marrow in this report is lower than in most other studies. This is explained 
by a different stage distribution of the patient population, methodological aspects 
and traditional markers for aggressiveness  such as ER/PgR negativity and 
histologic grade 3, were less frequently registered in this study. Differences in the 
use of negative controls might explain some of the variations in the reported rate of 
Bone Marrow positives. The choice of monoclonal antibodies for detection and the 
morphologic criteria used for the scoring of tumor cells may also influence the 
results and also short follow up times as being an important limiting factor for 
exploring the clinical value of DTC detection. This study concluded that DTC had 
an independent prognostic value  in  breast cancer management. 
Braun.S et al 2005 (Table B) had done a pooled analysis of Bone Marrow 
micrometastasis in Breast Cancer. A total of 4703 patients were studied of which 
1438 patients (13.21%) were positive for DTC. Of the 224 patients(4.76%) in the 
age group of 20-35yrs, 78(34.8%) had DTC, of 1454 patients (30.91%) in the age 
group of 36-50yrs, 484(33.3%) had DTC, of 1980 patients (42.1%) in the age 
group of 51-65yrs, 485(29.5%) had DTC and of 1045 patients(22.21%) above 
65yrs, 291(27.8%) had DTC. The P value was 0.001 which was statistically 
significant. Of these 4703 patients, 1579 (33.5%) were in the premenopausal age 
and 3124 (66.5%) patients were in the postmenopausal age. Of the premenopausal 
group 31(13.4%) patients were positive for DTC while 921 (29.5%) patients in the 
postmenopausal age group were positive for DTC. The P value was 0.001 which 
showed a significant correlation between menopausal status and DTC. 
Of the 2725 patients (58%) who had no lymphnode metastasis 719 (26.4%) 
had DTC while 1101patients (23.4%) with N1 level lymphnode metastasis 330 
(30%) had DTC, 469 patients (9.9%) with N2 level lymphnode metastasis, 185 
(39.4%) had DTC and 408 patients (8.6%) with N3 lymphnode metastasis, 294 
(50%) had DTC. The P value was 0.001 which was reported as significant. Of 
2507 patients with T1 tumour status, 633 patients (25.2%) had DTC, while 1706 
patients (36.2%) with T2 tumour status, 568 (33.3%) had DTC, 263 patients with 
T3 tumour status, 100 (38%) were positive for DTC and 227 patients with T4 
tumour status, 137 patients (60.4%) had DTC. The P value was <0.001, which 
shows an increased incidence of DTC with higher tumour status. Of the 4703 
patients studied 3605 patients (76.6%) had ductal carcinoma not otherwise 
specified, of which 1108 patients (30.7%) were positive for  DTC. Of the 4703 
cases, 693 patients had grade I tumour of which 156 (22.5%) were positive for 
DTC, 2141 had grade II tumour of which 641 (29.9%) were positive for DTC, 
1462 had grade III tumour of which 504 (34.5%) were positive for DTC. In 407 
patients the histological grade was not known and those patients were negative for 
DTC. The P value was 0.001 which was reported statistically significant. Of the 
923 patients who were negative for hormonal receptors, 979 patients (29.4%) were 
positive for DTC.  
Of the 3326 patients who were positive for any one of the receptors, 318 
patients (34.5%) were positive for DTC. The P value was 0.003 which showed a 
positive correlation. This study enrolled nine clinical studies and found strong 
evidence of the independent, adverse prognostic significance of the presence of 
bone marrow micrometastasis at the time of the initial diagnosis of operable breast  
TABLE B: CLINICOPATHOLOGICAL CORRELATION OF THE PATIENT 
AS IN THE STUDY OF - BRAUN.S. et al 2005 
CHARACTERISTIC   
  
TOTAL BM-DTC p-VALUE 
NO % NO %   
AGE AT DIAGNOSIS 
 
20-35 224 4.76 78 34.8 
0.001 
36-50 1454 30.91 484 33.3 
51-65 1980 42.1 485 29.5 
>65 1045 22.21 291 27.8 
MENOPAUSAL STATUS 
PRE 1579 33.5 31 13.4 
0.02 
POST 3124 66.5 921 29.5 
LYMPHNODE STATUS 
N0 2725 58 719 26.4 
0.001 
N1 1101 23.4 330 30 
N2 469 9.9 185 39.4 
N3 408 8.6 294 50 
TUMOUR STATUS 
T1 2507 53.3 633 25.2 
<0.001 
T2 1706 36.2 568 33.3 
T3 263 5.5 100 38 
T4 227 4.8 137 60.4 
HISTOLOGY 
 
DUCTAL 3605 76.6 1108 30.7 
0.08 LOBULAR 646 13.7 203 31.4 
OTHERS 452 9.6 55 12.6 
HISTOLOGICAL GRADE 
 
I 693 14.7 156 22.5 
<0.001 
 
II 2141 45.5 641 29.9 
III 1462 31 504 34.5 




POSITIVE 3326 70.7 318 34.5 
0.003 
 
NEGATIVE  923 19.6 979 29.4 
UNKNOWN 454 9.6 0 0 
 
Braun.S, Florial.D, Vogel. et al A pooled Analysis of Bone Marrow 
Micro-metastasis in Breast Cancer; New Eng J Med 2005; 353; 793-802 
  
cancer. In conclusion, this study also prescribed  the prognostic value of the 
presence of bone marrow DTCs’ and opined that DTC could be useful in the 
design of trials of the adjuvant treatment for breast cancer. 
Naume B et al 2001 (Table C) did a prospective analysis of clinical 
relevance of detection of isolated tumor cells in 920 breast cancer patients. Of 
these 108 patients (13.21) were positive for DTC. Of these patients 266(29.5%) 
were premenopausal and 564(62.6%) were postmenopausal while in 71(7.8%) 
patients the menopausal status was not known. Of the premenopausal patient 32 
(13.6%) patients were positive for DTC while 70(13.8%) in the post menopausal 
patients were positive for DTC. The P value was 0.906 which was reported as not 
significant.  
Of 567 patients (40%) had no lymphnode metastasis of which 51 patients 
(9.9%) had DTC. Of the 185 patients (24%) with N1 level lymphnode metastasis 
27 (15.6%) had DTC, 114 patients (36%) with N2&N3 level lymphnode 
metastasis, 31 (28.4%) had DTC while in 35 patients (3.9%) the lymphnode status 
was not known and they were all negative for DTC. The P value was <0.0005 
which showed a significant increase in DTC presence with higher lymphnode 
status. Of the 530 patients with T1 tumour status 56 (11.2%) had DTC,  of 267 
patients (29.3%) with T2 tumour status, 38 patients(15%) had DTC and of 55 
patients with a combined tumour status of T3&T4 , 12 patients(22.6%) were 
positive for DTC. The P value was 0.013 which showed a significant association 
between DTC and tumour status. Of the patients studied 662 patients(72%) had 
ductal carcinoma not otherwise specified, of which 81 patients (12.9%) were 
positive for  DTC. 
Of the 214 patients who had grade I tumour; 19 patients (9.5%) were 
positive for DTC, Of the 417 patients with grade II tumour, 59 patients (14.7%) 
were positive for DTC and of the 217 patients with grade III tumour, 31 patients 
(14.9%) were positive for DTC.  The P value was 0.013 and hence a significant 
association between DTC and histological grade.  
Of the 222 patients who were ER negative, 34 (16.8%) were positive for 
DTC while of the 625 patients who were ER positive, 71 (12.2%) were positive for 
DTC. The P value was 0.092, hence reported as statistically not significant. Of the 
347 patients who were PR negative, 48 (15.1%) were positive for DTC while of 
the 494 patients who were PR positive, 48 (15.1%) were positive for DTC. The P 
value was 0.157 which is not statistically significant. Of the 159 patients(20.1%) 
who showed  lymphovascular permeation, DTC was positive in 26 patients 
(17.4%), while 72 patients (12.6%) who were positive for DTC did not show any  
lymphovascular permeation. P value was 0.045 which shows a significant 
association between DTC and vascular invasion.  
This study concluded that (1) In node-negative patients, a markedly higher 
frequency of DTCs in Bone Marrow was observed among patients with receptor-
negative primary tumors, (2) The lower frequency of DTCs in ER and/or PgR 
positive patients could be expected because it has been observed previously that 
early metastatic relapse is less frequent in hormone receptor-positive breast cancer. 
(3) The reported incidence of DTCs in Bone Marrow in breast cancer patients has 
varied considerably in different studies and may be attributed to (a)  number of 
mono nuclear cells analyzed (b) expression of antigen used for detection of DTCs, 
(c) specificity of the monoclonal antibody used (d) sensitivity and specificity of the  
TABLE C: CLINICOPATHOLOGICAL CORRELATION OF THE PATIENT 











PRE 266 29.5 32 13.6 
0.906 POST 564 62.6 70 13.8 





N0 567 40 51 9.9 
<0.0005 
 
N1 185 24 27 15.6 
N2&N3 114 36 31 28.4 




T1 530 58.2 56 11.2 
0.013 T2 267 29.3 38 15 




DUCTAL 662 72 81 12.9 
0.238 LOBULAR 165 17.9 26 16.6 
OTHERS 46 5 4 9.1 
HISTOLOGICAL GRADE 
  
I 214 25.2 19 9.5 
0.013 II 417 49.2 59 14.7 




POSITIVE 625 73.8 71 12.2 
0.092 NEGATIVE 222 26.2 34 16.8 




POSITIVE 494 58.7 54 11.7 
0.157 NEGATIVE 347 41.3 48 15.1 




POSITIVE 624 78.5 75 12 
0.055 NEGATIVE  170 21.4 30 17 




POSITIVE 159 20.1 26 17.4 
0.045 NEGATIVE 609 76.9 72 12.6 
UNKNOWN 24 3 0 0 
 
Bjørn Naume,2 Elin Borgen, Gunnar Kvalheim et al.Detection of Isolated 
Tumor Cells in Bone Marrow in Early-StageBreast Carcinoma Patients: 
Comparison with Preoperative Clinical Parameters and Primary Tumor 
Characteristics1 Clinical Cancer Research 2001;7:4122–4129. 
method (e) use of negative controls (f) accuracy of the screening process and 
evaluation of immunopositive cells and (g) stage distribution in the patient series. 
Jean-Yves Pierga et al 2004 (Table D) studied the clinical significance of 
immunocytochemical detection of tumor cells using digital microscopy in 
peripheral blood and bone marrow of breast cancer patients in 114 patients of 
whom 67 patients (59%) were positive for DTC. Of 114 patients 75 patients’ 
clinicopathological characteristics were correlated with DTC. Of these 43(57%) 
were premenopausal and 32(43%) were postmenopausal. Of the premenopausal 
group 26(60.5%) patients were positive for DTC while 11(34%) patients were 
positive for DTC in the postmenopausal age group. The P value was 0.024 which 
was reported as a significant association between menopausal status and DTC. Of 
the 36 patients (48%) who had no lymphnode metastasis, 16 (44.5%) had DTC, 
while of the 32patients (43%) with N1 level lymphnode metastasis, 
16patients(50%) had DTC and 7 patients (9%) with N2 level lymphnode 
metastasis, 5 patients (71.5%) had DTC. The P value was 0.879 which was 
reported as not statistically significant. Of the 39 patients with T1 & T2 tumour 
status 13 (33%) had DTC while of the 20 patients(27%) with T3 tumour status 12 
(60%) had DTC. Of 16 patients with tumour status of T4 12 (75%) were positive 
for DTC. The P value was 0.35 which was reported as not significant. Of 75 
patients studied 65 patients (87%) had Ductal carcinoma Not Otherwise Specified. 
Of 12 patients with grade I tumours 5(42%) were positive for DTC, while of 27 
patients with gradeII tumour 10 (37%) were positive for DTC and of 34 patients 
with grade III tumour 22 (65%) were positive for DTC. The P value was 0.079 
which is not statistically significant. 
TABLE D: CLINICOPATHOLOGICAL CORRELATION OF THE PATIENT 




NO % NO % 
MENOPAUSAL STATUS 
PRE 43 57 26 60.5 
0.024 POST 32 43 11 34 
UNKNOWN 0 0 0 0 
LYMPHNODE STATUS 
N0 36 48 16 44.5 
0.879 N1 32 43 16 50 
N2 7 9 5 71.5 
TUMOUR STATUS 
T1/T2 39 52 13 33 
0.35 T3 20 27 12 60 
T4 16 21 12 75 
HISTOLOGY 
DUCTAL 65 87 33 51 
0.573 LOBULAR 9 12 4 44 
OTHERS 1 1 0 0 
HISTOLOGICAL GRADE 
I 12 16 5 42 
0.079 II 27 36 10 37 
III 34 45 22 65 
ER STATUS 
POSITIVE 44 59 17 38.6 
0.026 
NEGATIVE 31 41 20 64.5 
PR STATUS 
POSITIVE 14 19 6 43 
0.328 
NEGATIVE 45 60 26 58 
VASCULAR INVASION 
POSITIVE 33 44 21 64 
0.043 
NEGATIVE 40 53 16 40 
 
Jean-Yves Pierga,Charlyne Bonneton,Anne Vincent-Salomon et a. 
lClinical Significance of Immunocytochemical Detection of Tumor Cells Using 
Digital Microscopy in Peripheral Blood and BoneMarrow of Breast Cancer 
Patients.Clinical Cancer Research.2004;10, 1392–1400. 
  
Of the 31 patients who were ER negative, 20 (64.5%) were positive for 
DTC and of the 44 patients who were ER positive, 17 (38.6%) were positive for 
DTC. The P value was 0.026 which was reported significant. Of the 45 patients 
who were PR negative, 26 patients (58%) were positive for DTC. Of the 14 
patients who were PR positive, 6 cases (43%) were positive for DTC.P value was 
0.328 which is not statistically significant. Of the 33 patients(44%) who showed  
lymphovascular permeation, DTC was positive in 21 patients (64%), while 16 
patients (40%) were positive for DTC but did not show any  lymphovascular 
permeation. P value was 0.043 and hence there was significant association 
between vascular invasion and DTC in this study.  This study detailed that the 
prognostic factors for disease-free survival in the series were classical i.e. tumor 
size; clinical nodal status; tumor emboli and Bone Marrow micrometastatic 
disease. Pathological nodal status was not a significant prognostic factor in this 
series. In conclusion, this study supported the prognostic value of the presence of 
bone marrow micrometastasis in breast cancer prognostication. 
Diel Ingo. J. et al.,1996 (Table E) did a study on micrometastatic breast 
cancer cells in bone marrow at primary surgery in 727 patients of whom 315 
(43.32%) were positive for DTC. Of 727 patients studied 296(40.94%) were 
premenopausal and 431(59%) were postmenopausal. In the premenopausal group 
112(38%) were positive for DTC while 203(47%) were positive for DTC in the 
postmenopausal group. The P value was 0.01 reported as significant.  
Of 360 patients (49.5%) without lymphnode metastasis, 112 (31%) had 
DTC while of 367patients (50.4%) with lymphnode metastasis 203 (55%) had 
DTC. The P value was 0.001, hence reported significant. Of 258 patients with T1 
tumour status, 77 (30%) had DTC, of 323 patients (44.4%) with T2 tumour status, 
137 (42%) had DTC, of 69 patients with T3 tumour status, 43 (62%) had DTC and 
of 77 patients with T4 tumour status, 58 (75%) had DTC. The P value was <0.001 
which was reported significant. Of 403 patients with grade I & II tumours 159 
(39%) were positive for DTC while of 431 patients with grade III tumour 144 
(52%) were positive for DTC. The P value was 0.01, which was a significant 
correlation.  
Of 207 patients who were ER negative, 91 (44%) were positive for DTC 
and of 410 patients who were ER positive, 186 (45%) were positive for DTC. The 
P value was 0.74, hence was reported as not significant. Of 247 patients who were 
PR negative,119 (48%) were positive for DTC while of 341patients who were PR 
positive, 145 (42%) were positive for DTC. The P value was 0.17, hence was 
reported as not significant.  
This study mainly aimed at prognostication in comparison with the nodal 
status and concluded that the worst prognosis was associated with the presence of 
tumor cells in both axillary lymph nodes and bone marrow.  
The results of the study provided consistent evidence that DTC is a 
prognostic indicator independent of the nodal status. 
 
  
TABLE E: CLINICOPATHOLOGICAL CORRELATION OF THE PATIENT_ 
DIEL.J.ET AL., 1996 
CHARACTERISTIC 
TOTAL BM-DTC p-
VALUE NO % NO % 
MENOPAUSAL STATUS PRE 296 41 112 38 0.01 
POST 431 59 203 47 
LYMPHNODE STATUS N0 360 49.5 112 31 0.001 
N+ 367 50.4 203 55 
TUMOUR STATUS T1 258 35.4 77 30 <0.001 
T2 323 44.4 137 42 
T3 69 9.4 43 62 
T4 77 10.5 58 75 
HISTOLOGICAL GRADE I&II 403 48 159 39 0.01 
III 431 52 144 52 
ER STATUS 410 66.4 186 45 410 0.74 
207 33.5 91 44 207 
PR STATUS POSITIVE 341 57.9 145 42 0.17 
NEGATIVE 247 42 119 48 
 
Ingo J. Diel, Manfred Kaufmann, Serban D. Costa. Et al., 
Micrometastatic Breast Cancer Cells in Bone Marrow at Primary Surgery: 
Prognostic Value in Comparison With Nodal Status.Journal of the National 
Cancer Institute.1996; 88:1652-1658 
Our Study 2009-2010. (Table F) We did a prospective analysis of clinical 
relevance of detection of isolated tumor cells in the bone marrow of breast cancer 
patients at primary diagnosis in 50 patients. Of these 50 patients studied, 13 (26%) 
were positive for DTC. The mean age of patients in our study is 52 years. Of the 
50 patients studied, 24 patients were below 52 years of whom 3 (12.5%) were 
positive for DTC while 26 patients were above 52 years of age of whom 10 
patients (38.5%) were positive for DTC. The age and occurrence of DTC in the 
bone marrow statistically correlated (P value 0.037). This indicates that the risk of 
DTC is increased with the age of the patient. The study of Braun S et al (2005) 
made a contrasting observation that the occurrence of DTC was higher in ages 
younger than 51 years. This observation may be attributable to the variation in our 
study size and selection methodologies. The existence of a racial factor to this 
observation also needs to be studied.  
Of the 50 patients studied, 21 patients (42%) were premenopausal while 29 
patients (58%) were postmenopausal. Of the premenopausal patients, 2 (9.5%) 
were positive for DTC while of the postmenopausal patients 11(37.9%) were 
positive for DTC. Menopausal status and the presence of disseminated tumour 
cells revealed that there is an increased incidence of DTC in postmenopausal age 
(p Value 0.024). This correlated well with the study of Braun S et al 2005 and Deil 
IJ et al 1996 while this was in contrast with the study of Pierga A et al 2004 in 
which the premenopausal patients predominanted. Weidswang G et al 2003 and 
Naume B et al 2001 did not report any significant correlations in their studies. The 
South Indian rural population included in our study have to be further evaluated 
for unique racial and socioeconomic parameters that may be reasons for the 
significant increase in DTC in the postmenopausal group in our study. 
Of the 50 patients studied, 18 patients (36%) had no lymphnode metastasis 
of which one of the patients (5.6%) had DTC. Of 17patients (34%) with N1 level 
lymphnode metastasis, 6patients (35.3%) had DTC and of 15 patients (30%) with 
N2 level lymphnode metastasis, 6 patients (40%) had DTC. There were no N3 
level lymphnode metastases in our study group. The association between DTC and 
lymphnode status was significant (p value 0.045). This indicates that the risk of 
DTC increases with a higher nodal status. This correlates with the study of Braun 
S et al 2005, Wiedswang.G et al 2003, Naume B et al 2001 and Deil IJ et al 1996. 
Pierga A et al 2004 did not report any such significant correlation between DTC 
and lymphnode status in their study. In our study the comparison of the nodal 
status and presence of DTC indicated that there was an increased concordance in 
the presence of tumor cells in axillary lymph nodes and bone marrow with 
increasing incidence with a higher lymphnode status. This result of our study 
provides significant evidence that DTC is an independent prognostic indicator. 
The mastectomy specimens were examined, and it was correlated that of the 
50 patients studied, 12 patients (24%) had a primary tumour size of less than 2cms 
(T1), of whom 1 patient (8.3%) had DTC. Of the 11 patients (22%)  with a 
primary tumour size of more than 2cms but less than 5cms (T2), 1 patient (9.1%) 
had DTC. Of the 15 patients (30%) with a primary tumour size of more than 5cms 
(T3), 4 patients (26.7%) had DTC and of 12 patients (24%) with a variable 
primary tumour sizes with skin or chest wall infiltrates (T4), 7 patients (58.3%) 
had DTC. The tumour size and the occurrence of DTC were correlated statistically 
in our study (p value 0.018).  This indicates that the frequency of DTC was more 
with a higher tumour size (T). This correlated well with the studies of Braun S et al 
2005, Wiedswang.G et al 2003, Naume B et al 2001and Deil IJ et al 1996. Pierga 
A et al 2004 did not report any correlation between DTC and tumour status in their 
study. Our study indicates that there is a progressive increase of incidence of DTC 
with the increase in size of the tumour with a maximal incidence associated with 
T4 tumours. This compares well with existing tested prognostic indices and hence 
contributes to the value of DTC as a prognostic indicator. 
Of the 50 patients studied all 50 patients (100%) had Infiltrating Ductal 
Carcinoma of Breast – Not Otherwise Specified type. These cases were graded 
using the modified Bloom and Richardson’s System of Grading (Elston CW et al 
loc.cit 1991). Of the 16 patients(32%) studied with grade I tumor , 1 patient (10%) 
had DTC, while of the 20 patients (40%)  with Grade II tumour  5 patients (24%) 
had DTC, and of the 14 patients (28%) with Grade III tumour  7 patients (66%) 
had DTC. Statistical correlation (p value 0.0u24) indicates that the risk of DTC 
increases with higher histological grades. This correlated well with the studies of 
Braun S et al 2005, Naume B et al 2001 and Deil IJ et al 1996, while this was in 
contrast with observation of Pierga A et al 2004 in which the grade I tumor 
predominated. Wiedswang.G et al 2003 did not report any significant correlation 
with the histological grades in their study. In our study, the progressive increase of 
incidence of DTC with the increase in tumour grade and a maximal association 
with grade III tumours was observed. This signifies that DTC has an independent 
prognostic value. 
Of the 50 mastectomy specimens studied, 46 were subjected to hormonal 
receptor status evaluation. Of these, 33 patients were ER negative. In this group, 
13 patients (34.4%) were positive for DTC. Of the 13 patients who were ER 
positive, no DTC was detected. The occurrence of DTC and ER status was 
statistically correlated (p value 0.011). This indicates that the risk of DTC 
increased in ER negative tumours. This correlated well with the study 
of,Wiedswang.G et al 2003, Naume B et al 2001, Pierga A et al 2004. But Diel J et 
al 1996 did not report any such correlation between DTC and ER status in their 
study. 
Of the 24 patients who were PR negative, 12 patients (50%) were positive 
for DTC. Of the 22 patients who were PR positive, 1 patient (4.54%) was positive 
for DTC. The frequency of DTC and PR status was statistically correlated (p value 
0.001). This indicates that the risk of DTC  increased in PR negative tumours. This 
correlated well with the study of Wiedswang.G et al 2003, Naume B et al 2001, 
Pierga A et al 2004. But Diel J et al 1996 did not report any such correlation 
between DTC and PR status in their study.  Both ER and PR hormonal receptor 
status was computed together. Of the 46 patients subjected to both hormonal 
evaluations, 13 patients (71.73%) were positive for hormonal status and none of 
them had DTC. Of the 33 patients (71.73%) who were negative for both hormone 
receptors, 13 patients (39.39%) had DTC. This is statistically significant (p value 
0.011). This indicates that the risk of DTC increased with hormone negative 
tumours. This correlated well with the study of Wiedswang.G et al 2003, Naume B 
et al 2001, Pierga A et al 2004. But Diel J et al 1996 did not report any such 
correlation between DTC and hormonal status in their study. The patients who was 
ER positive or PR positive or Positive for both ER and PR were found to have a 
lesser incidence of DTC in the bone marrow. This signifies that the tumour cells 
were more bound to the primary site with a hormone positive state and correlates 
with the tumour biology. In our study, significantly the absence of both or either of 
the receptors i.e. ER & PR was associated with increased DTC incidence in the 
bone marrow. This is ample evidence that the current methods of prognostication 
are significant while DTC adds value to their use and can act as an independent 
index. This observation of ours also throws light on the tumour cell growth and 
behaviour. The breast cancer cells with ER / PR receptors on the surface are prone 
to less metastasis than ER / PR negative cells. This has to be considered for further 
research. 
Of the 17 patients (34%) who showed obvious lymphovascular permeation, 
DTC was positive in 12 patients (70.6%), while 1 patient (3%) was positive for 
DTC, but did not show any obvious lymphovascular permeation. This was 
statistically significant (p value 0.000) and correlated well with the studies of 
Naume B et al 2001, Pierga A et al 2004. But Wiedswang G et al 2003, did not 
report any such correlation. Braun S et al 2005 and Diel J et al 1996 did not 
correlate vascular invasion with DTC in their studies.  In our study we considered 
the correlation between lymphovascular permeation and presence of DTC in the 
bone marrow as significant.  
For all the 50 patients included in this study, we had done a bone marrow 
aspiration and a clot section as described. Of the 50 cases studied only 1 patient 
had DTC in the clot sections, while 13 patients had DTC in the aspirate smears. 
This shows that the clot section had lesser predictive value compared to aspirate 
smears. But, with better concentration methods and use of density gradient 
enrichment methods of bone marrow material, the sensitivity and specificity of the 
clot section is bound to improve. The detection rate of DTC with Pan Cytokeratin 
immunocytochemical staining in our study was 26%, this correlated with the 
studies of Redding WH et al (1983)
105
 28%, Untch M et al (1999)
106
 28% and 
Coombes RJ et al loc.cit (1986) 23%. Redding used MUC, while Untch used 
CK18/CK2 as the immmunocytochemical marker in their studies. 
The total study size of 50 patients in our study was spread over a smaller 
period of time. The observations and inferences drawn during the course of our 
study are hence limited by the study size and time. But considering the significant 
conclusions derived in this  study and its significance in patient management, a 
detailed prospective study with follow up is proposed. 
Our study in comparison with the study of various other authors referred to 
in our discussion have highlighted the following intricacies stressing the 
importance of DTC in Breast Cancer prognosis. The combination of tumor size / T 
status, Hormone receptor status in relation with ER and PR, Lymphnode status / N 
status, Tumour grade, Lymphovascular permeation and presence of DTC in the 
Bone Marrow can categorize patients into a good prognosis group and a high-risk 
group which can be applied for predicting early disease progression. The node 
positive patients (N1 or more) with a Tumor size greater than 2 cm (T2 or More), 
receptor negativity, and BM-positive status predict a high relapse rate.  
  
TABLE F: CLINICOPATHOLOGICAL CORRELATION OF THE 






NO % NO % 
AGE AT DIAGNOSIS 
<52 24 48 3 12.5 
0.037 
52&above 26 52 10 38.5 
MENOPAUSAL 
STATUS 
PRE 21 42 2 9.5 
0.024 POST 29 58 11 37.9 
UNKNOWN 0 0 0 0 
LYMPHNODE 
STATUS 
N0 18 36 1 5.6 
0.045 
N1 17 34 6 35.3 
N2 15 30 6 40 
N3 0 0 0 0 
NX 0 0 0 0 
TUMOUR STATUS 
T1 12 24 1 8.3 
0.018 
T2 11 22 1 9.1 
T3 15 30 4 26.7 
T4 12 24 7 58.3 
TX 0 0 0 0 
HISTOLOGY 
DUCTAL 50 100 13 100 
- LOBULAR 0 0 0 0 
OTHERS 0 0 0 0 
HISTOLOGICAL 
GRADE 
I 16 32 1 10 
0.024 
II 20 40 5 24 
III 14 28 7 66 
UNKNOWN 0 0 0 0 
ESTROGEN 
RECEPTOR STATUS 
POSITIVE 13 26 0 0 
0.011 NEGATIVE 33 66 13 39.39 
UNKNOWN 4 8 0 0 
PROGESTERONE 
RECEPTOR STATUS 
POSITIVE 22 44 1 4.54 
0.001 NEGATIVE 24 48 12 50 
UNKNOWN 4 8.7 0 0 
HORMONAL STATUS 
POSITIVE 13 26 0 0 
0.011 NEGATIVE 33 66 13 39.39 
UNKNOWN 4 8 0 0 
VASCULAR 
INVASION 
POSITIVE 17 34 12 70.6 
0.000 NEGATIVE 33 66 1 3 
UNKNOWN 0 0 0 0 
TYPE OF SURGERY 
SEG 1 2 0 0 
0.015 SIMPLE 15 30 8 53.3 
MOD RAD 34 68 5 14.7 
 
Our study also confirms that the occurrence of DTC in bone marrow 
predicts the future systemic relapses and death from breast cancer in consonance 
with existing prognostic factors and hence the detection of these cells can be 
considered as an independent prognostic factor. The proportion of positive Bone 
Marrow DTC in our report is lower than in most other studies. This is explained by 
a different age and menopausal distribution of our patient population, variation in 
certain methodological aspects, social, regional and racial factors which were not 
registered in our study. The choice of monoclonal antibodies for detection and the 
morphologic criteria used for the scoring of tumour cells may also have influenced 
our results and also the small study size and the short time period may be 
important limiting factors in our study. This study yet confirms that the 
independent prognostic value of detection of DTC in Bone Marrow in breast 
cancer is significant and has to be studied widely in the Indian context with 
specific references to the regional, racial and socio-economic factors that may play 
a significant role. 
  
SUMMARY AND CONCLUSION 
Our study has highlighted the following important observations indicating the 
importance of DTC in Breast Cancer Prognosis.  
1. Our Study concludes that the incidence of DTC is higher in post 
menopausal patients with Breast Carcinoma. 
2. Our Study concludes that there is a significant concordance in the presence 
of tumor cells in lymph nodes and the presence of DTCs’ in bone marrow 
and the incidence increased with increasing lymphnode status with a 
maximal association for N2 tumours. 
3. Our Study concludes that there is a progressive increase in the incidence of 
DTC with increase in tumour size with a maximal association for T4 
tumours. 
4. Our Study concludes that there is a progressive increase of incidence of 
DTC in relation to tumour grade and a maximal association with 
histological grade III tumours.  
5. Our Study concludes that the incidence of DTC increase with Hormone 
receptor negative tumours, while in concordance patients who were positive 
for Hormone receptors had a lesser incidence of DTC in the bone marrow. 
The relationship between breast cancer hormone receptors and intercellular 
adherence and hence metastasis has to be considered for further research. 
6. Our Study concludes that lymphovascular permeation has a positive and 
significant relationship with DTC in the Bone Marrow.  
7. Our Study concludes that clot sections have lesser predictive value 
compared to aspirate smears. But with better methodology, the sensitivity 
and specificity of clot sections may improve.  
8. Our Study concludes that the evaluation of Bone Marrow for the 
disseminated tumour cells correlates with most other standard prognostic 
indices.   
9.  Our study concludes that the evaluation of bonemarrow for the 
disseminated tumour cells, can assist in categorization of breast cancer 
patients into low risk and high-risk groups, for a better prediction of early 
disease progression and relapse.  
10. Our study also concludes that disseminated tumour cells in Bone Marrow 
could have an independent prognostic value and has to be studied widely in 
the Indian context with specific reference to the regional, racial and 
socioeconomic factors.  
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BM No  : 
Name     :        Hospital No     :  
Age       :        Cancer OP No : 
Sex        :        Ward / Unit  
CLINICAL HISTORY  
• Duration  
• Nipple discharge 
• Family history of breast or ovarian cancer 
• Prior breast cancer diagnosis  
• Prior breast surgery (Site, Diagnosis, Rx) 
• History of exposure to radiation / Chemotherapy / hormonal therapy  
• Current pregnancy / Lactation 
• Menopausal status  
CLINICAL EXAMINATION  
General condition  
Lump : size   
  Quadrant  
  Surface 
  Fixity  
Lymph node : Axillary  
  Cervical  
  Other  
Hepatosplenomegaly  
CLINICAL STAGING  
 
INVESTIGATIONS  
Hb%      Total  
TC%      Direct  
DC      Indirect 
RBC      SGOT 
Platelets     SGPT 
ESR      ALP 
MCV      T. Protein 
MCH      Albumin 
MCHC     Globulin  
P. Smear  
 
IMAGING STUDIES  










BIOPSY       x 
Specimen        
Lumpectomy       
Simple mastectomy      
Radical mastectomy       
 
PROCEDURE  
Core biopsy / wedge biopsy     
Lumpectomy       
Total mastectomy      
 
Lymph node sampling 
No lymph nodes present     
Sentinel lymph node(s)      
Axillary dissection       
(Partial or complete)  
 
Specimen integrity 
Single intact specimen     
Fragmented  
(Margins cannot be evaluated)    
 
Specimen size  
Greatest dimension     
Specimen laterality 
 Right        
 Left       
 Not specified      
 
Tumor Size       
 
Tumor site  
 Upper outer quadrant     
 Lower outer quadrant     
 Upper inner quadrant     
 Lower inner quadrant     
 Central       
 Nipple       
Tumor focality   
 Single focus      
 Multiple focus      
 No of foci      
 Sizes of individual foci.    
MACROSCOPIC AND MICROSCOPIC EXTENT OF TUMOR SKIN  
• Skin is not present        
• Invasive ca does not invade the skin      
• Invades the skin without skin ulceration     
• Invades the skin with skin ulceration      
• Satellite foci of skin invasion.      
Skeletal muscle 
• No skeletal muscle present       
• Skeletal muscle present & is free of carcinoma    
• Carcinoma invades skeletal muscle      
Architectural pattern  
Solid            
Papillary          
Micropapillary         
Cribriform          
Comedo           
Other (Specify)          
Nuclear Grade 
 Grade I          
 Grade II         
 Grade III         
Necrosis  
 Not identified         
 Present, focal         
 Present, central        
Margins 
 Margins cannot be assessed        
 Margins uninvolved by ca       
 Distance from closet margins    
 Margin positive for invasive ca      
* Specify margin  
* Extent        focal / minimal / extensive   
Lymphovascular invasion - Not identified / present / indeterminate  
Perineural invasion    Not identified / Present Indeterminate  
Lymph node status       
No nodes           
If present : Total No of lymph nodes    
   
Extra nodal extension    Not identified / Present / Indeterminate.  
      
TNM  Staging  
Distant metastasis     Present / Not Present 
Ancillary studies       
ER / PR 
Status of residual breast  
BONE MARROW  
Procedure  - Iliac         
   Biliac        
   Sternum        
   Amount collected  
   Anticoagulant used 
   Fixative used 
Processing : Direct smear    - H & E     
      Leishman     
      Special stain    
      IHC     
Centrifuged Concentrate Smear - H & E     
Stain used     leishman    
      Special stain    
      IHC     
Clot sections     - H & E     
Stain used      Leishman    
      Special stain    







HAEMATOXYLIN AND EOSIN STAINING PROCEDURE 
1. Dewax sections, hydrated through graded alcohols to water 
2. Stained in alum haematoxylin   for 7 min 
3. Washed well in running tap water  until sections blue for 5 minutes 
4. Differentiated in acid alcohol for 5 seconds 
5. Washed well in running tap water until sections blue for 5minutes 
6. Stained in 1%Eosin Y for 3minutes 
7. Washed in running tap water for 5minutes 
8. Dehydrated through alcohols, cleared and mounted 
John D.Bancroft, Alan Stevens; “Theory and Practice of 
Histological Techniques”, 4
th






                  
 
APPENDIX -3 
STANDARDS FOR DETECTION OF DISSEMINATED TUMOUR 
CELLS BY IMMUNOCYTOCHEMISTRY 
1. A Bone Marrow sample of 5ml to 10 ml is aspirated from anterior and/or 
posterior iliac crests and collected in tubes containing either heparin or 
EDTA and stored within the range from +4°C to +20°C until further 
processing of the samples, preferably within 24 hours. 
2. Smears were air-dried at room temperature and then immunostained. For 
fixation, we used acetone for 10 minutes or methanol for 15 minutes.  
3. For immuno-staining, the anti-CK-antibodies A45-B/B3 or AE1/AE3, 
used together with the APAAP detection system. Blocking of endogenous 
alkaline phosphatase by using commercially available blocking kits.  
4. Breast cancer cells were admixed to bone marrow samples from 
individuals without cancer is used for positive staining controls. Positive 
cells are defined as Cytokeratin-positive/immunocytochemically positive 
cells with disseminated tumor cell morphology. The bonemarrow slides 
are interpreted as positive when Disseminated tumor cells are present in 
bone marrow.  
Tanja Fehm, Stephan Braun et al; A concept for the standardized 
detection of disseminated tumor cells in bone marrow from patients 





































1 LATHA 27634/09 35/F PRE 3 T4 0 N0 M0 DUCTAL IIIB 2 - MRM + + + - _ _
2 CHELLATHAI 31748/09 35/F PRE 7 T3 5 N2 M0 DUCTAL IIIA 2 + MRM - + - - _ _
3 LAKSHMIAMMAL 33643/09 65/F POST 6 T3 4 N2 M0 DUCTAL IIIA 2 + SM - _ - + _ +
4 USHA 34558/09 48/F PRE 3 T2 0 N0 M0 DUCTAL IIA 1 - MRM + + + - _ -
5 ARUMUGATHAMMAL 37072/09 48/F PRE 4 T2 1 N1 M0 DUCTAL IIB 1 _ MRM NA NA NA - _ -
6 MALLIKA 36904/09 39/F PRE 8 T3 0 N0 M0 DUCTAL IIB 3 - SM + + + - _ -
7 SENDU 37252/09 48/F PRE 7 T4 5 N2 M0 DUCTAL IIIB 1 + MRM - + - - _ -
8 LAKSHMIAMMAL 44698/09 50/F PRE 4.2 T2 0 N0 M0 DUCTAL IIA 2 - MRM + _ + - _ -
9 MANOGARAM 41706/09 70/F POST 5.5 T3 0 N0 M0 DUCTAL IIB 2 - MRM _ _ _ + _ +
10 PONKILI 43521/09 45/F PRE 1.2 T1 2 N1 M0 DUCTAL IIA 1 - MRM - + - - _ -
11 MARIAMMAL 45835/09 46/F PRE 7.5 T3 3 N1 M0 DUCTAL IIIA 2 - MRM + + + - _ -
12 MUTHULAKSHMI 44534/09 45/F PRE 2 T1 0 N0 M0 DUCTAL I 1 - SM - _ - - _ -
13 CHELLATAI 45511/09 46/F PRE 1.8 T1 2 N1 M0 DUCTAL IIA 2 - MRM + + + - _ -
14 MARIAMMAL 45535/09 70/F POST 6 T4 5 N2 M0 DUCTAL IIIB 3 + SM - + - + _ +
15 MUTUMARI 46366/09 39/F PRE 1.5 T1 0 N0 M0 DUCTAL I 3 - MRM NA NA NA - _ -
16 CHELLAMAL 51198/09 55/F POST 5 T4 2 N1 M0 DUCTAL IIIB 3 + MRM - _ - + _ +
17 MUTHUALKSHMI 48054/09 53/F POST 2 T1 5 N2 M0 DUCTAL IIIA 1 - SM - _ - - _ -
18 MAKMUTHAL BEGAM 54187/09 40/F PRE 6 T4 1 N1 M0 DUCTAL IIIB 2 + MRM _ _ _ + _ +
19 SAKINA BEGAM 47094/09 29/F PRE 1.8 T1 0 N0 M0 DUCTAL I 1 - MRM - + - - _ -
20 POOLAMMAL 55555/09 50/F POST 6 T3 2 N1 M0 DUCTAL IIIA 1 - MRM + _ + - _ -
21 PARVATHI 53861/09 60/F POST 5 T4 0 N0 M0 DUCTAL IIIB 3 - MRM - _ - - _ -
22 ARUMUGAM 52762/10 43/F PRE 3 T2 0 N0 M0 DUCTAL IIA 1 - MRM _ + _ - _ -
23 ATHILAKSHMI 19978/10 45/F POST 1.5 T1 1 N1 M0 DUCTAL IIA 1 + SM - _ - + _ +
24 RAMALAKSHMI 14152/10 53/F POST 5 T4 3 N1 M0 DUCTAL IIIB 3 + MRM - _ - + _ +
25 KALA 16525/10 38/F PRE 2 T1 0 N0 M0 DUCTAL I 2 - MRM - + - - _ -





























26 SUBBAMMAL 8023/10 65/F POST 5.5 T3 7 N2 M0 DUCTAL IIIA 3 + MRM + + + - _ -
27 ESAKKIAMMAL 15258/10 58/F POST 2.8 T2 6 N2 M0 DUCTAL IIIA 2 + SM - _ - + + +
28 AVUDAIAMMAL 14397/10 35/F PRE 6 T3 2 N1 M0 DUCTAL IIIA 2 + SM - _ - + _ +
29 SHANMUGASUNDARAVADIVU 11190/10 61/F POST 5 T4 6 N2 M0 DUCTAL IIIB 3 + SM - _ - + _ +
30 MUPIDATHY 12651/10 58/F POST 4.5 T3 0 N0 M0 DUCTAL IIB 3 - MRM + _ + - __ -
31 NIRMALA 12163/10 58/F POST 3 T2 1 N1 M0 DUCTAL IIB 2 - MRM _ + _ - _ -
32 AYYAMMAL 14267/10 65/F POST 6 T3 4 N2 M0 DUCTAL IIIA 2 + SM - _ - - _ -
33 ESAKKIAMMAL 16258/10 58/F POST 5.5 T3 0 N0 M0 DUCTAL IIB 1 - MRM - + - - _ -
34 MARIYAL 13564/10 65/F POST 3.5 T2 3 N1 M0 DUCTAL IIB 2 - SM NA NA NA + _ -
35 RAMATHILAGAM 15683/10 45/F PRE 4 T2 3 N1 M0 DUCTAL IIB 1 - MRM _ + _ - _ -
36 SANKARAMMAL 16386/10 55/F POST 6 T3 4 N2 M0 DUCTAL IIIA 2 - SM - + - - _ -
37 SUSAIAMMAL 16253/10 50/F PRE 2 T1 0 N0 M0 DUCTAL I 1 - MRM + _ + - _ -
38 VELMAYIL 16362/10 65/F POST 5 T4 0 N0 M0 DUCTAL IIIB 3 - SEGM - _ - - _ -
39 POONAMMAL 18347/10 54/F POST 6.5 T3 3 N1 M0 DUCTAL IIIA 2 - MRM + + + - _ -
40 SIVAGAMI 21564/10 61/F POST 3.5 T2 2 N1 M0 DUCTAL IIB 2 - MRM _ _ _ + _ -
41 KUMARI 19345/10 58/F POST 1.8 T1 0 N0 M0 DUCTAL I 1 - SM NA NA NA - _ -
42 NAGOORAMMAL 20325/10 55/F POST 4.5 T2 3 N1 M0 DUCTAL IIB 2 - MRM - + - - _ -
43 PICHAMMAL 22567/10 56/F POST 6 T3 4 N2 M0 DUCTAL IIIA 3 + MRM - _ - + _ +
44 YOGAMMAL 21298/10 53/F POST 6 T4 4 N2 M0 DUCTAL IIIB 3 + MRM + + + - _ -
45 MAHESWARY 21532/10 48/F PRE 1.5 T1 0 N0 M0 DUCTAL I 1 - MRM _ + _ - _ -
46 ESAKKIAMMAL 2199/10 57/F POST 4.8 T4 3 N1 M0 DUCTAL IIIB 3 + SM - _ - + _ +
47 DIRAVIYAM 22011/10 60/F POST 6.2 T3 5 N2 M0 DUCTAL IIIA 2 - MRM - _ - - _ -
48 MUTHAMMAL 22112/10 56/F POST 1.5 T1 0 N0 M0 DUCTAL I 1 - MRM + + + + _ -
49 SAKTHI 28011/10 48/F PRE 2.5 T2 6 N2 M0 DUCTAL IIIA 2 - MRM - _ - - _ -
50 RAJAM 29056/10 55/F POST 5 T4 5 N2 M0 DUCTAL IIIB 3 + SM - _ - + _ +
